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ABSTRACT 
With the rapid increase in the number of CT scans being performed worldwide, the importance of 
dose reduction to the radiosensitive breast tissue during these procedures is becoming a critical 
factor in ensuring that the induction of breast cancer in this modality is minimised. This study utilised 
a novel geometric phantom that allowed rapid modification of the size of the breasts to analyse the 
effectiveness of various dose reduction techniques under a variety of different circumstances from 
paediatric patients to larger breasted patients. Doses were accurately measured throughout the 
entire breast and chest area using over 300 individual TLD crystals, providing extremely 
comprehensive dose contour maps for CT scanning of the chest area.  
The efficiency of bismuth breast shields was investigated and it was found that an average dose 
reduction of 21% for small sized breasts and up to 44% for larger breasts could be achieved. A 
maximum dose reduction of 57% was found, which does confirm the manufacturer’s claims. The 
breast shields did create additional quantitative noise in the diagnostic regions of interest, as well as 
qualitative noise in the form of streaking or beam hardening artefacts. The study found that lower 
breast doses could be achieved for a consistent noise value by simply manually reducing the tube 
mA. 
Dose modulation on the Philips 64 CT scanner was also found to be an effective way to reduce the 
breast dose with reductions of between 40% and 50% depending on the type of dose modulation 
used. Dose modulation coupled with the breast shield created an even greater dose reduction, with 
certain techniques providing almost an 80% reduction in breast dose, though this was coupled with a 
significant increase in noise. 
Based on the findings in this study, it is believed that further analysis on acceptable levels of noise is 
needed before a definitive position can be taken on the clinical use of bismuth breast shields. Other 
methods are available to the operators that provide equivalent levels of dose reduction to the breast 
tissue, whilst providing lower levels of noise in the clinical regions of interest. 
 
 
 
 
2 
1 INTRODUCTION 
1.1 Aim 
 
The overall aim of this study is to determine the most effective way to reduce the radiation dose to 
the breast during non-breast related CT scans, whilst still maintaining a suitable image quality. This 
study will attempt to compare the doses and noise of various protocols that can be used for dose 
reduction, including tube current modulation, bismuth breast shields and manual reduction of tube 
current. Each method will be analysed individually in Section 3 and a final comparison will be 
presented in Section 4. 
 
1.2 Radiation and Cancer 
 
One of the first thoughts many people have when they hear a discussion on radiation is cancer. Many 
years of media attention to the dramatic potential of nuclear material has left this lasting impression 
in people’s minds. Is there cause for so much alarm and negativity? Are people aware that the same 
isotopes that are released during a nuclear power plant meltdown[1] are used to cure individuals of 
pre-existing cancers, or that the gamma ray emissions from a radioactive transport container, that 
cause such public outcry[2], are almost identical to those used to diagnose a multitude of ailments 
and injuries?  
This first section will discuss the basics of ionising radiation and introduce the associated hazards. 
Specifically relating to this study, will be the discussion on breast cancer and breast cancer trends in 
Australia. 
1.2.1 Ionising Radiation 
Ionising Radiation can be of the form of electromagnetic waves or sub-atomic particles that have the 
ability to create charged atoms, ions, by the removal of electrons. X-rays are one type of ionising 
radiation that are produced and utilised in diagnostic radiology, amongst other applications. X-rays 
are also described as photon radiation, and have many of the basic properties of any type of 
electromagnetic radiation; they travel at the speed of light, they only weakly interact with matter 
and are thus very penetrating, they have no mass and no charge and they propagate and transfer 
energy by fluctuating electric and magnetic fields. 
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X-rays are produced primarily by the deceleration of charged particles, negative electrons in the case 
of an X-ray machine, as they experience the attractive force of the positively charge atomic nucleus 
of a high density material. As these electrons are deviated from their initial path the deceleration 
results in an energy loss that is emitted in the form of a photon of radiation. This type of radiation is 
described as Bremsstrahlung radiation. Bremsstrahlung production results in a spectrum of X-ray 
energies up to the maximum energy of the electrons used to create the spectrum. 
Characteristic radiation is the second process that creates diagnostic X-rays. When a charged particle 
has sufficient energy to eject an inner shell electron from a target atom, that inner shell electron will 
be replaced by a higher energy electron existing in an outer shell band. The resultant energy loss of 
the outer shell electron falling to a lower energy band is emitted in the form of a photon of radiation, 
and will have energy unique to the target atom, thus the term characteristic X-ray. 
The end result of these two creation processes is a spectrum of radiation with specific peaks 
corresponding to the characteristic properties of the target atoms. Diagnostic X-ray machines used 
for both general radiography as well as computed tomography are generated in this manner. 
1.2.2 Biological Damage from Ionising Radiation 
One of the main mechanisms through which biological organisms are damaged by ionising radiation 
is caused by the radiolysis of water molecules[3] operating through the mechanism described below; 
   γ 
    H2O →HOH
+ + e- → OH + H → H2O2 
Hydrogen Peroxide (H2O2) often forms hydroxyl free radicals (OH
-) within biological organisms which 
are highly reactive and have the ability to destroy molecular structures, resulting in the subsequent 
damage to living cells[4].  
Most tissues and organs within the human body can sustain a large number of cell deaths with no 
adverse effects; although if the number increases substantially there will be a loss of tissue function. 
These type of effects were previously known as deterministic effects[5], and are now referred to as 
tissue reactions[6] . Apart from a few well documented cases [7-10], tissue reactions are not likely to 
be observed during routine diagnostic imaging such as CT.  
If the cellular damage caused directly or indirectly, as outlined above, by ionizing radiation does not 
result in cell death there is a probability that the cell could be modified and lead to the development 
of a cancer. These types of effects are known as stochastic effects. The probability of developing a 
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cancer as a result of an exposure to ionizing radiation is thought to be roughly proportional to the 
dose, and “probably has no threshold”[5]. This basic assumption is known as the Linear No Threshold 
(LNT) hypothesis and has been adopted by the major international bodies that offer 
recommendations on radiation matters including the International Commission on Radiological 
Protection (ICRP), National Council on Radiation Protection and Measurement (NCRP), International 
Atomic Energy Agency (IAEA) and the United Nations Scientific Committee on the Effects of Atomic 
Radiation (UNSCEAR). Each of these major bodies, although adopting the LNT hypothesis, has 
acknowledged that it may overestimate risks at low doses. Other major international societies have 
also stated strongly that the LNT theory may not be an accurate descriptor at low doses including the 
Health Physics Society (HPS)[11], France Academy of Medicine and the American Nuclear Society[12]. 
 
1.2.3 Accuracy of the LNT Theory 
Much of our knowledge of the carcinogenic effects of relatively low doses of radiation comes from 
studies of atomic bomb survivors, specifically residents of Hiroshima and Nagasaki during August,  
1945[13]. It is widely acknowledged that radiation at low doses is, at best, a weak carcinogen[4, 14-
16], but it has more recently been associated with a positive effect, which in general terms states 
that a small amount of radiation is beneficial to a biological organism[17-19], otherwise known as 
Radiation Hormesis.  A recent BEIR (Biological Effects of Ionizing Radiation) report[20] acknowledged 
several imperfections with the Japanese data. This includes the applicability of data from a Japanese 
population, undergoing the stresses of war, and with inherently different baseline cancer rates, as 
well as the inability to accurately determine the individual doses received by survivors[21], but this 
report reiterated that the LNT hypothesis is still the most computationally convenient starting point 
when estimating radiation risks[20].  However persuasive the evidence for Hormesis appears, the 
LNT model has been accepted as a conservative and prudent approach to address the delayed health 
effects of low doses of radiation [22]. This is the same ideology adopted across Europe and America 
and has recently been termed the precautionary principle[23], which is summed up by the simple 
term; better safe than sorry[24]. With the current regulatory system in place within Australia based 
on this system it is unlikely to change in the near future, thus, the LNT theory has been adopted in 
this thesis. 
 
1.2.4 Recommendations of the ICRP 
The most recent general recommendations published by the ICRP, ICRP 103[25], include a list of 
tissue weighting factors (ωt). These are designed to take into account the contribution of various 
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organs and tissues to the overall detriment from radiation induced cancer[26]. ICRP 103 was 
published in 2007 and was the update to the previous general recommendations, ICRP 60[27], which 
were published in 1991. Table 1-1 compares the previous recommended tissue weighting factors 
with the most current. 
 tissue weighting factor, ωt relative detriment from 
ICRP 103[26] 
Organ/Tissue ωt ICRP 60 ωt ICRP 103 Male Female 
Gonads 0.20 0.08 0.053 0.068 
Bone Marrow (red) 0.12 0.12 0.144 0.080 
Colon 0.12 0.12 0.138 0.044 
Lung 0.12 0.12 0.124 0.182 
Stomach 0.12 0.12 0.120 0.117 
Breast 0.05 0.12 0.000 0.240 
Remainder 0.05 0.12 0.256 0.155 
Bladder 0.05 0.04 0.036 0.024 
Liver 0.05 0.04 0.075 0.026 
Oesophagus 0.05 0.04 0.026 0.021 
Thyroid 0.05 0.04 0.010 0.031 
Skin 0.01 0.01 0.008 0.006 
Bone Surface 0.01 0.01 0.011 0.008 
Brain  0.01   
Salivary Glands  0.01   
Table 1-1: Tissue weighting factors used to calculate effective dose. 
Of particular importance to this study is the marked increase in the tissue weighting factor for the 
breast.  This large increase was attributed to the most recent generation of epidemiological studies 
carried out on the atomic bomb survivors of Japan [28, 29]. The implication is that breast tissue 
provides a far greater relative risk to total cancer detriment than was previously thought. Potentially 
of even greater importance is the relative detriment attributed to this particular tissue. With the ICRP 
estimating that breast cancer accounts for almost one quarter of all cancer detriment in females. 
These two factors highlight the necessity of ensuring doses of ionising radiation to the female breast 
tissue within the population are minimised, and emphasise the importance of dose reduction 
techniques, such as breast shields, in clinical applications. 
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1.2.5 Breast Cancer 
Breast cancer is the most common cancer among Australian women, with over 13,000 new cases 
diagnosed each year. Of diagnosed cases, slightly less than 100 are found in men. It also leads to the 
deaths of over 2,600 people each year, making it the most common fatal cancer in females. The 
future is estimated to bring a 22% increase in the number of diagnosed cases per year by 2015, which 
is consistent with a 240% increase in breast cancers diagnosed from 1982 to 2007[30-32].  
 
 
Figure 1-1: Breast cancer incident rate per 100,000[33] 
Figure 1-1 above shows the worldwide incidence rate of breast cancer, by country. It is interesting to 
note the prevalence of incidence rates in developed countries, which may be indicative of the 
presence of thorough screening programs, or could show an underlying genetic susceptibility in 
women of Anglo-Saxon descent. 
 
1.2.6 Trends in modern women 
Current estimates of radiation dose and risk estimates, specifically in mammography, are based on 
findings from the late 1970s which found that the breast is composed of 50% adipose, or fatty, tissue 
and 50% glandular tissue[34]. More recent studies have indicated that the volume of tissue at 
carcinogenic risk, stated as glandular tissue for the purposes of this study, is closer to 25% for the 
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UK[35]. Another important facet of the Bryant et al. [35] work was the variance of adipose tissue in 
the breasts of women of different ages.  
It is noted that the percentage of glandular tissue within the female breast decreases with age. In 
fact, the breasts of young women prior to the completion of puberty is predominately glandular[36, 
37]. Another dramatic change occurs at the onset of menopause where much of the previous 
glandular tissue is replaced by adipose tissue[37, 38]. This makes the protection of younger breasts 
of even greater importance. 
Other studies have shown a greater percentage of adipose tissue in larger breast[39]. Several studies 
have noted increases in the average breast size of women over time[39-41] and two main causes 
were identified - increasing obesity in the population and problems with new technology including 
tilting compression paddles within mammography units, which have skewed the average breast size. 
The general increase in obesity obviously means a greater percentage of adipose tissue within the 
individual, but it is important to identify where this fat is stored within the breast area. Subcutaneous 
fat describes a layer of fat that lies just underneath the skin, and is present over the entire body. 
Within the breast this layer forms a protective barrier over the remainder of the breast tissue, and is 
predominately present in the upper and outer quadrant of the breast[37, 42, 43]. There is also a 
great deal of fat intermixed within the general breast area, especially in overweight individuals[38, 
43]. Figure 1-2 below shows the general distinction between the fatty and glandular tissue[44]. Thus 
the general trend of increasing obesity in Australia[45] results in an increase of the intermingled 
adipose tissue as well as the outer layer of subcutaneous fat. It is both the intermingled adipose 
tissue and the varying thickness of subcutaneous fat which makes determining the exact location of 
the ‘at risk’ glandular tissue impossible to accurately determine for a population. 
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Figure 1-2: Diagram of female breast showing distinction between adipose and glandular tissue[44]. 
 
1.3 CT – Basic principles  
Traditional radiography utilises the attenuation of an X-ray beam to project an image onto a flat two 
dimensional screen. This can result in the loss of a large amount of information in the third 
dimension. One of the most revolutionary steps that has been taken in this field since the discovery 
of X-rays by Wilhelm Rontgen in 1895, has been the adoption of Computed Tomography (CT) which 
negates the need for a purely two dimensional representation of a three dimensional object. The 
basic principle of CT scanning is that the internal structures of an object are reconstructed by 
combining multiple slices of that object[46]. The technology has advanced rapidly since its first 
application in 1972 and continues to advance in line with the development of more powerful 
computer hardware. 
 
CT scanners are typically designed with a patient table that moves through a circular “gantry”. This 
gantry houses a rotating ring of detectors and an X-ray tube that spins around the patient as they are 
moved laterally through the gantry by the table. Typically each time the ring has rotated 360 degrees 
a slice has been acquired. Modern helical or spiral scanners allow the patient to move continuously 
through the gantry, rather than stopping at regular intervals to allow the scan rotation to occur. This 
also means there are no gaps between slice scans, as could be the case in standard axial scanning if 
contiguous scan sections were not used. Multi-slice scanners are now the standard technology 
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available, with commercially available CT scanners able to image up to 256 slices simultaneously. This 
can result in much faster scan times and greater resolution[46]. New technology has generally lead to 
a reduction in the patient radiation dose from diagnostic imaging, though the opposite has been the 
case for CT[47], although the recent trend does indicate reductions in dose. 
 
1.3.1 Doses from CT 
By its very nature, CT scanning typically results in much greater doses to the patient than traditional 
radiography. Typical effective doses for a chest CT scan range from 5-20 mSv depending on the 
protocol selected, where a regular diagnostic chest X-ray is usually going to give less than 
0.1mSv[47].  
A recent study by Einstein et al[14] looked at the Lifetime Attributable Risk (LAR) of cancer for a 
variety of different aged women who underwent chest CT scans (specifically Computed Tomography 
Coronary Angiogram) using a 64 Slice CT scanner. Doses to the breast were estimated at between 50-
80mSv, which is approximately twice the expected dose in this study, and the LAR for women is 
shown below in Table 1-2. 
Women Age LAR Cancer 
20 1 in 143 (0.7%) 
40 1 in 284 (0.35%) 
60 1 in 466 (0.22%) 
80 1 in 1338 (0.075%) 
Table 1-2: LAR for women of various ages for breast exposure of 50-80mSv[14]. 
A similar study by Feng et al [48] was conducted on a paediatric phantom using TLDs. Effective Doses 
were calculated to be between 3.0 and 3.5mSv, and a maximum LAR of 0.155% for 5 year old females 
was established.  
 
It is estimated in the US that almost 69 million CT scans were performed in 2007, which corresponds 
to an average growth of approximately 8% for the preceding 5 years[49]. This is for a corresponding 
population of about 300 million[50].The Cancer Council of Australia estimates that although the total 
number of scans per head of population in Australia is likely to be less than the US, the growth rate 
of scans since 2000 is greater at 12%[51].  
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Brenner et al [4] estimates that 1.5 to 2.0% of all cancers in the US are attributable to CT scan 
studies. A large number of scans as mentioned in this study are due to generic full body screening, 
though the regulations in Australia currently prohibit CT scans without the referral of a Medical 
Professional, except in a few special circumstances[52]. This is likely to mean Australia will have a 
lower population dose attributable to these scans, but does not lessen the LAR for each individual 
patient. 
With such a large number of these scans being performed, and a significant risk of breast cancer 
present in each scan, it is imperative that the dose to the breast, and thus the chance of developing a 
fatal cancer, is reduced as much as possible. 
1.3.2 Noise (and Image Quality) in CT 
 
The CT image is generated by the process briefly described in Section 1.3. After the basic process, the 
linear attenuation coefficient for each pixel in the image is normalised to that of water, which is 
assigned a value of zero. These normalised values are often referred to as the CT-number, or 
Hounsfield number. The Hounsfield numbers perform a similar role to that of optical density in film 
radiography, or the exposure index for digital radiography, and provide a measure of the lightness or 
darkness of each pixel, which controls the contrast of the image[46].  
When a perfectly uniform material is imaged the CT-number for each pixel should theoretically be 
identical, but in practice these values do fluctuate around a given mean. It is this random variation 
that we call noise[46, 53] and it limits the ability to see small differences in contrast. Noise does 
come in other variants, such as qualitative noise or artefacts in the image, though for the purposes of 
this study noise will be referring to the statistical fluctuations in Hounsfield numbers. 
Some studies, such as that conducted by Keil et al[54], use a Radiologist to determine the extent of 
noise added to the image by the inclusion of a variety of CT shields. This type of analysis relies on 
training, experience and instinct to determine the final quality of the image. The end result is likely to 
be a fairly good qualitative analysis. A similar approach has also been used by Hopper et al[55], 
where the emphasis on these types of analyses is placed in the detection of visible artefacts that may 
be introduced by beam hardening, or streaking caused by creases or bends in the shield[55, 56]. It 
was decided that this method of noise comparison would be insufficient for this study for a variety of 
reasons. First, the existence of these types of artefacts does not necessarily create an image that is 
not of diagnostic quality. It was observed by this study and others[54, 57] that streaking would 
occasionally occur into the breast itself, though the idea behind this project is to reduce to breast 
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dose when the breast is not the primary object of interest. Second, a large number of assessors 
would be needed to ensure an unbiased and accurate representation of the images was undertaken, 
which would seriously impact on time constraints for this study, as well as the Radiologists. Last, 
rather than relying on a qualitative assessment, a method which produced quantitative results allows 
for a direct comparison between multiple techniques and modalities, giving far greater accuracy to 
any conclusions made. 
Multiple national and international bodies[53, 58, 59] use the standard deviation of the Hounsfield 
numbers in a given Region of Interest (ROI) as a measure of the quality of the image, in determining 
the performance levels of a CT scanner. It is generally included in a typical QA procedure for all new 
and existing equipment in Australia. For this type of testing a water phantom is commonly used, and 
the deviation from the mean of zero should be minimal for the aggregate of all pixels in a given ROI. 
This same methodology has been adopted by several research groups in this field [56, 60-62]. A 
variety of different anthropomorphic phantoms and cadavers were used in these studies, though for 
each one a particular ROI was selected and the standard deviation of the CT-number was used as an 
indication of the noise level for different scan protocols. These studies indicate the greater the 
deviation from the mean, the larger the noise value present in the image. 
This commonly used method has been employed in this study to give a quantitative figure to the 
noise value within the image under the various testing conditions outlined in this work. 
 
1.4 Methods to Reduce Dose 
 
1.4.1 General methods 
The easiest and most effective way to minimise the risk of radiation induced cancer in individuals and 
the population as a whole is to not perform the examination in the first place. Various studies have 
estimated that almost a third of all CT requests are considered unnecessary [4, 63, 64]. It has also 
been shown that referring physicians have little or no understanding of the levels of radiation their 
patients are exposed to, nor of the risks associated with these levels of exposure [65, 66].  
The parameters of the scan are of importance in optimising radiation dose and include the tube 
current, rotation time, kV, pitch and area of body to be imaged, however, there are many others. 
Protocols should be created that allow for various sized individuals, specifically catering for paediatric 
patients as children are more susceptible to the hazards from radiation. Many of these factors can be 
modified by the operator, so suitable operator training on dose reduction is essential. The value of 
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Diagnostic Reference Levels (DRL’s) in reducing overall population dose has also been noted. The 
ICRP has stated that DRL’s should be used by all relevant authorised bodies to reduce the number of 
unjustified high dose exposures and to promote good dose practice[67]. The manufacturers of CT 
equipment also have an obligation to ensure their equipment provides radiation doses as low as 
reasonably achievable. 
 
1.4.2 Dose Reduction technologies 
The major CT manufacturers are all aware of the importance of dose reduction for each individual 
patient, and have all developed various technologies to help minimise these doses. As the tube 
current is directly proportional to the dose, a reduction in the current, or mA, results in a 
proportional decrease in dose. The four major CT manufacturers have developed a system where the 
current is reduced to areas in which less X-rays are needed to maintain a constant image quality or a 
constant noise.  
These four major companies all implement similar ideologies in their technologies and have 
developed a variety of techniques that are called a variety of different names, but equate to the 
same basic principle. These principles include advanced software that can improve the image quality 
during the processing phase, also known as iterative reconstruction, collimators that actively change 
based on the scan time, built in protocols for low dose or paediatric studies, reduction of scatter 
radiation from the tube focal point and a heavy emphasis on operator training. A brief summary is 
shown below in Table 1-3. 
 
Manufacturer Current modulation 
Processing techniques 
to minimise dose 
Other 
Siemens [68] 
X-Care 
 
Lowers the current when the tube is 
imaging sensitive organs, such as the 
breast or the eye. Dose reduction to 
the breast is reduced by 30-40%. 
IRIS 
 
Additional algorithm 
to reduce image noise. 
Adaptive Dose 
Shields 
 
Temporary 
blocking the 
beam that is not 
used for image 
reconstruction 
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GE[69] 
AutomA 
 
Current modulation is applied from 
the parameters found in the scout 
scan, and a lower number of X-rays 
are employed in low attenuating 
areas without increasing noise. 
ASiR 
 
Additional algorithm 
to reduce image noise. 
Clear paediatric 
protocol 
selections. 
Philips [70] 
Automatic Current Selection (ACS) 
 
A tool that automatically selects the 
current based on the attenuating 
properties of the patient. 
 
 
iDose 
 
Additional algorithm 
to reduce image noise. 
 
Detailed operator 
training on Dose 
Optimisation. 
Toshiba [71] 
Real E.C. 
 
Using the scout scan (Scanogram) a 
profile of the signal is displayed, 
which corresponds to attenuation. 
Low dose modes can then be applied 
in applicable areas. 
 
AIDR 
 
Additional algorithm 
to reduce image noise. 
 
Reduction of 
scattered X-rays 
from the focal 
point within the 
tube itself. 
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Table 1-3: Summary of the four main CT manufacturers and a variety of dose reduction techniques employed in each. 
The manufacturers advertising material estimates dose reduction from Tube Current Modulation to 
be between 40 and 60%[68, 70, 71]. Studies specifically looking at the dose to the breast have found 
reductions of 9.4% using tube current modulation, specifically on a Siemens Scanner[56] and the 
total effective dose from this study was found to reduce by 7.0% when current modulation was used. 
 
1.4.3 Patient Shields 
The use of shields in diagnostic radiology has fairly limited applications in respect to minimising the 
radiation dose to the patient. Shields can be used to provide protection to radio-sensitive organs that 
may be close to the primary beam, but are not considered essential to the image[72]. In this aspect 
the radiosensitive organs are protected from the primary beam, though it is considered far better 
practice to ensure the beam is collimated to the region of interest only. Thus any shielding in this 
sense would be of use only to prevent additional secondary, or even tertiary, back-scatter.  
The use of shielding in CT scanning though does have far more potential to lower the radiation dose 
to a patient. Often the organ of interest is deep within the body, and other sensitive tissues are 
required to be traversed by the incident primary beam before the beam can be attenuated in the 
organ of interest. The difference between regular radiography and CT is that the organ of interest 
will continue to be irradiated though multiple directions, so a shield will only block the primary beam 
from one direction. This allows for the potential to have a shielding material that will preferentially 
remove the low energy photons that would ordinarily deposit dose into the patient, without adding 
significantly to the image quality. The quality of the beam will be improved in this process which 
should mean that image quality of the organ of interest is still maintained. 
The ARPANSA published Safety Guide associated with Diagnostic Radiology for the Australian Code of 
Practice[52] recommends the use of shields in all modes of diagnostic radiology for the radiosensitive 
organs such as the gonads, thyroid, eye and breast[73]. It is acknowledged that for regular 
radiography the use of these shields is discouraged when the shield will likely obscure the desired 
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information, such as ovarian shields in an abdominal X-ray. There is a requirement for gonad shields 
to have a minimum lead equivalence of 0.5mm at 150kVp, though no such stipulation is made for CT 
shielding. It is further stated that significant protection is afforded only when the primary beam is 
directed towards structures outside the immediate area of interest, which as stated above, is 
contrary to best practice[73]. 
In regards to CT examinations the code states that the operators should consider using breast, 
thyroid and eye shields, as significant dose reductions have been shown, whilst maintaining suitable 
image quality[47]. It does note that breast shields are unlikely to result in dose reductions when tube 
current modulation is used, since the presence of high density material will likely drive the current 
higher to compensate.  
The most current position paper released by the American Association of Physicists in Medicine 
(AAPM) discusses the disadvantages of using bismuth breast shields and recommends that 
alternative dose reduction methodologies should be used when possible[74]. 
The only commonly available commercial shielding is the “Attenurad” shield by F&L Medical 
Products, available through the Australian distributor Imaging Solutions. This shield comes in shapes 
for the eye, thyroid and the breast, and utilises a 1mm thick bismuth impregnated synthetic rubber 
covering, attached to a foam base[75]. It is this breast shield that is occasionally used in the 
Radiology Department at Sir Charles Gairdner Hospital, and it was subsequently used for the 
purposes of this study. The lead Equivalence of this shield, from a radiation protection perspective, 
was found to be 0.0753mm Pb for 120kVp photons, see Section 3.1 for details. 
 
1.4.4 Effectiveness of Dose Reduction Techniques 
 
The distributors of the commercial Attenurad breast shields state that dose reduction to the breast 
can be up to 57% by the use of these bismuth impregnated sheets[75]. Independent studies [15, 56, 
57, 61, 62, 76-80] also unanimously agree that the use of these shields does indeed reduce the 
absorbed radiation dose to the breast. Although this dose reduction is commonly acknowledged, the 
degree to which the shields reduce the dose varies between groups, and many studies do not 
recommend their use in clinical applications due to the existence of other methods to reduce dose, 
or due to the degradation of image quality created by the shields. 
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Table A-1 in the Appendix summarises ten different studies that have looked at the dose reduction 
capabilities of these breast shields. One of the highest dose reductions was found by Hopper et 
al.[78] at 57%, which may be where the manufacturers sourced their marketing information. 
Although the greatest reduction was found by Parker et al.[79] to be 61%. The smallest dose 
reduction was found by Fricke et al.[15], and was still fairly significant at 29%. The average dose 
reduction shown by these breast shields from the studies surveyed was 44.5%.  
Perhaps of greater importance is the authors’ recommendation of whether or not the shields should 
be incorporated into clinical use. Of these ten studies, seven gave recommendations that the shields 
should be used clinically, three did not. Of these three, Cordova [57] stated that Bismuth breast 
shields induced artefacts into the underlying chest structures and had the potential to render CT 
examinations unusable. Both Geleijns[61] and Vollmar[56] found statistical increases in Quantitative 
noise values, as well as inducing streak or beam hardening artefacts into the images. They also stated 
that a greater dose reduction would be experienced by the breast tissue by using a lower fixed 
current during the examination whilst keeping a noise value consistent with that found under the 
presence of the shields.  
The majority of the studies concluded favourably in terms of the clinical use of these breast shields. 
Although it should be noted, that of these seven, only three of the studies looked directly at the 
creation of noise in the images when making their final conclusions. Fricke[15], Hohl[76] and 
Hurwitz[62] found that the level of quantitative noise did not increase to levels that would result in 
an un-diagnostic quality image. Each study did show some minor noise increase in the chest region 
when using breast shields, though to our knowledge there are no guidelines that stipulate acceptable 
noise levels for accurate diagnosis. It is likely that this would vary between equipment and 
Radiologists. Once again, none of these three studies found a significant increase in detrimental 
artefacts by the use of these shields. Although Hopper[77] did not look directly at noise values, they 
did acknowledge that care needed to be taken in the placement of the shield to ensure that no sharp 
folds or large air gaps are created underneath the shield, which could lead to artefacts in the 
diagnostic portion of the image. 
The absorbed dose in diagnostic imaging is approximately proportional to the kVp2, and directly 
proportional to the mA. Hurwitz[62] showed that an extra 20% reduction in breast dose can be 
achieved when the voltage was lowered from 140 to 120kVp, when used in conjunction with a 
bismuth breast shield. Rampado[81] showed a 7% lower chest dose when values of 100kVp were 
used, without a breast shield. It is also clear that a reduction in the current of a fixed mA scan will 
lead to a proportional reduction in dose, but as stated above, the noise level also increases as the 
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current decreases. It has been noted also, that the dose reduction effects of a breast shield cannot be 
equivalently achieved by reducing the tube current alone[82]. This finding by Kim et al[82] is 
explained by comparing the photon spectrum of a standard exposure, bismuth breast shielded 
exposure and a reduced mAs exposure. Kim found that the extent to which the low energy photons 
were preferentially removed by the bismuth shield resulted in lower patient doses, without removing 
the higher peak energy photons used for image creation. In direct contrast to this statement, 
multiple studies[56, 61] have concluded that dose reduction can be more effectively achieved by 
direct mA reduction. 
Tube Current Modulation, or Dose Modulation, is a technology that automatically selects a current as 
the scan progresses. As discussed in Section 1.4.2 each manufacturer has a variety of methods to 
achieve this modulation. Studies have been done to ascertain the effectiveness of these 
technologies. One such method is to compare the modulated dose to a reference scan to determine 
the dose reduction capabilities of these methods [56, 62, 83]. Studies like that by Matsubara[83] do 
show that the use of Dose Modulation can decrease the breasts dose by over 50%, when compared 
to a reference scan. No mention of why the protocols in this scan were chosen has been given. We 
could presume that the reference scan is based on standard protocols used by the practice in 
question, though these protocols differ between locations, equipment and even operators, so the 
relevance would be practice specific only. Other studies have tried to compare the absorbed dose 
values under a variety of constant noise scans, and both Rampado[81] and Matsumoto[84], for 
example, conclude that dose modulation is an effective way to reduce to absorbed dose to a patient 
whilst still maintaining a suitable image quality.  
It is clear that there is significant debate over the use of these bismuth breast shields in clinical 
practice[85]. Although the dose reduction capabilities have been firmly established the controversy is 
in their ability to reduce the dose without causing significant noise and artefacts. This study will 
attempt to compare the doses and noise values under TCM to that received under fixed mA 
protocols, as well as compare the two different dose modulation techniques available on the Philips 
CT scanner. 
1.5 Paediatric Considerations 
Section 1.2 dealt with the stochastic risks that humans face when exposed to ionising radiation. ICRP 
estimates that the risk of developing a fatal radiation induced cancer is approximately 5% per Sv for 
the general population, but the risk is increased to closer to 15% if that exposure occurs in the first 
decade of an individual’s life[25]. Brenner et al[4] estimates that the risk of dying from cancer was 
increased by 0.35% when infants were exposed to a single abdominal CT scan. Other studies have 
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shown slightly lower LAR’s[48, 63, 86]. Regardless of the exact figures, there are two consistencies; 
younger people are more likely to develop fatal cancers from ionising radiation, and female children 
are at higher risk than males. 
This increase in risk for paediatric patients is likely due to two reasons. Firstly, cells that are most 
active and actively proliferating are much more sensitive to the negative effects of ionising 
radiation[87]. The additional radiosensitivity of children due to their greater rate of cell division is 
also coupled with second reason in that they have a longer life span ahead of them in which to 
develop a cancer[63].  
Manufacturers and operators have a responsibility to ensure that paediatric protocols are used 
wherever possible, which include lower kVp and lower tube current protocols. The Attenurad shield 
does in fact come in sizes and thicknesses specifically designed for paediatric imaging. The question 
still remains on whether or not patient shields will still be effective under these paediatric conditions. 
Both Coursey at al[88] and Lai et al [89] recommend that these shields are used in child CT scans, as 
dose reductions of 23-27% have been found for the breast tissue. A summary paper by Kim et al[82] 
is designed to provide guidance on the use of breast shields for paediatric studies, though 
unfortunately only 3 of the 13 research studies used for the paper were tested on paediatric 
protocols. The final conclusion of Kim et al is that in an appropriate setting, the use of bismuth 
shielding is a valuable tool to reduce the radiation risk in children.  
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2 METHODS & EQUIPMENT 
 
2.1 CT Scanner 
The CT scanner used in this study is a Philips Brilliance 64 slice model, as shown in Figure 2-1, which is 
housed in the Radiology Department of Sir Charles Gairdner Hospital. According to the commonly 
used Dosimetry Calculator, ImPACT CT version 1.0.3[90], the total effective dose to a patient 
undergoing a chest CT scan with the protocols used for the phantom analysis in this study is 16mSv. 
The calculation page is shown below in Figure 4-2. This does not represent the typical protocol 
routinely used for patients at SCGH. 
The Philips scanner consists of two different types of dose modulations. The first is termed DoseRight 
ACS which makes use of a reference image topogram to assess the patient’s attenuation in order to 
set the tube current. This mode is designed to maintain a constant image quality throughout the 
examination. Because this comparison is made with a reference image stored on initial set-up of the 
unit, it is difficult to compare scanning protocols between units[91]. There is also the potential to use 
a reference image that is higher quality than is needed, and thus higher doses could be used than 
what is actually necessary[91].  
The second type of modulation is known as DoseRight DOM, which provides either z-axis (Z DOM) or 
rotational (D DOM) automated exposures. Z DOM adjusts the mAs along the longitudinal, or Z, axis 
based on the scout scan taken before the diagnostic image scan. D DOM modulates the current 
during each rotation based on the symmetry of the patient or phantom. This modulation is carried 
out during the scan and will likely result in higher dose saving to objects that are rotationally 
asymmetrical[92].  
 
Figure 2-1: Philips Brilliance 64 Slice CT scanner 
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Figure 2-2: Dose calculations using the ImPACT program. 
 
It is interesting to note that by utilising the ICRP 60 recommendations for tissue weighting factors the 
total effective dose is reduced to 13mSv. The equivalent dose to the breast is calculated to be 
31mGy, as shown in Figure 2-2. 
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2.2 The Phantom 
 
Within the context of this research, a phantom is used to simulate the human body in order to 
improve our understanding of the radiation dose received by the body. The emphasis in this study is 
the breast tissue, and understanding the dosimetry of the breast during CT scanning. This is not a 
novel area of study and various commercially available phantoms [93-95] are available that can 
perform admirably under a variety of  situations. Unfortunately these phantoms are often expensive, 
but more importantly to quote one of the manufacturers; “Breast shapes are not natural”[95]. It was 
our opinion that the commercially available phantoms were not cost effective, nor had the requisite 
detail and flexibility that was essential for this study, thus a suitable phantom was manufactured. 
Other groups have noted the need for more flexibility in areas such as size and shape of the 
phantoms [96] or material properties [97], though nothing of particular specificity was easily 
discovered for shielding of breast tissue in CT. Future work in this area may justify the construction of 
an anthropomorphic phantom, though for the research goals of this study a geometrical phantom 
was sufficient. A variety of considerations were kept in mind when designing the phantom including 
the type of material to use in construction, the size and shape, the type of detector we would use 
and the general design of the phantom.  
 
2.2.1 Material Selection 
ICRU Report 44 [98] states that for phantoms designed to stimulate photon scatter in a human, or for 
embedding dosimeters for depth of dose measurements, that plastics meet the basic general 
requirements. These requirements include: 
• Relative homogeneity 
• That the mass density should be within about 10% of unity 
• That it should be relatively free of elements with Z > 20, to minimise production of 
fluorescent X-rays 
• Composed of a hydrogenous material 
• That linear attenuation coefficients should be within 5% of that for the simulated tissue. 
 
Relevant data for the tissues being simulated in this study is included in Table 2-1 below, with a 
comparison to Perspex also included.  
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Tissue 
Elemental Composition (% by mass)[36] Mass Density 
(kgm-3)[36] 
Attenuation 
coefficient 
μ/ρ [99-101] H C O 
Breast (whole) 
50/50* 
11.5 38.7 49.8 960 0.201 
Lung(Deflated) 10.3 10.5 74.9 1040  0.205 
Muscular 10.2 14.3 71 1050 0.205 
Water 11.2  88.8 1000 0.206 
Acrylic[98] 8.0 60 32 1170 0.197 
Table 2-1: Physical data for human tissue and Perspex. *water/lipid 
 
The Linear attenuation coefficients shown are for photons of 60keV, which is the nearest available 
data point to the average energy photon from the 120kVp beam used in this work. It should be noted 
that the actual average photon energy of the 120kVp beam is approximately 65keV[102, 103].  When 
comparing the basic properties of acrylic to the five points listed above, it is clear that it meets all 
these basic components. The Perspex blocks have almost perfect homogeneity, the density is 
consistent and falls to within almost 10% of that of the breast, lung and muscular tissue. There are no 
elements with atomic number greater than 20, Hydrogen makes up approximately 8% by weight of 
the total, and the attenuation coefficient is well within 5% of all the applicable tissue estimates. 
Perspex also has the added benefit of being highly machinable and is relatively cheaply and readily 
available, thus, it was chosen as the material of choice for the phantom.  
 
2.2.2 Size Selections 
One of the main criticisms we had with the breast attachments commercially available was their lack 
of relevance to typical Australian women’s breast in terms of size and shape. This is illustrated in 
Figure 2-3 below [104].  
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Figure 2-3: An example of a female breast phantom[104]. 
 
There is a general trend in the major western countries of the UK, US and Australia of increasing 
breast sizes over about the last 100 years [105-108]. Even recently, bra sizes have increased from a B 
cup in the 1950’s[107] and by one cup size since 2005 in Australia, with the reported average size of 
12DD in 2010[106]. Other sources have the average currently listed between a 12C up to a 12DD 
[105, 106, 109]. But in trying to relate these generic cup sizes to a mathematical basis for a geometric 
phantom is very difficult, as every country has different categorisation techniques, as does each 
individual manufacturing company. A second hurdle involves the size and shape of the breast whilst 
the patient is in a supine position undergoing the CT scan, which is not taken into account at all 
during the typical sizing process.  
The chest or abdominal phantom size used was a modification from the typical CTDI phantom used 
to simulate scatter in a CT. The size of the breast plate attachments were loosely chosen based on 
the circumference of a patient with B cup, D cup and E cup breast size, with shapes that were far 
more natural than such examples as in Figure 2-3 above.  
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The breast plate attachments were crafted into three sizes designated small, medium and large, 
which correspond to breast peak heights of 3cm, 5cm and 7cm. The depth of each attachment was 
70mm, though additional slices were also made for the medium breast plate only, which allowed us 
to increase the size of the breast in the “Z” direction by an additional amount. 6 additional slices each 
of 7.5mm thickness were created. Details are shown in Figure 2-4. 
 
2.2.3 Additional Design Considerations 
Once the basic design decisions regarding material and shape were made, the phantom needed to be 
constructed so it was able to perform our specific tasks as easily and efficiently as possible. This was 
largely shaped by our decision to use TLD rods, for reasons outlined in section 2.3, for the dosimetry.  
By keeping the initial phantom in two separate halves, it allowed for holes to be drilled into one face 
of each half. The TLD rod capsules were then inserted into one half of the phantom, with a small 
amount of the TLD capsules sticking out. The two halves where then brought together, leaving a solid 
Figure 2-4: A variety of pictures describing the phantom and breast attachment construction. 
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phantom with each TLD capsule held in place, directly in the middle of the phantom. This “Two 
Halves” approach had multiple benefits. It negated the need to drill a single large hole for each TLD 
through a large thickness of material in order to reach the centre of the phantom. Drilling through 
this type of acrylic material has the potential to warp the structure due to the heat generated, and 
the drill can deviate from a perfectly vertical line if drilling too far. Extracting the TLDs after 
measurement would also likely be difficult. There would also be a far greater amount of air created in 
the phantom, which could potentially affect the dose and image quality. 
The breast plate attachments were created to sit as seamlessly as possible directly on top of the 
existing phantom. The thickness in the “Z” direction was only 70mm, half that of the total torso 
phantom. This meant it was far easier to drill a single hole for the TLD capsules to be placed into. 
 
2.2.4 Phantom Summary 
The end result was the creation of phantom stages as outlined in Table 2-2. 
 
Phantom Description Used for Photograph 
Stage 1 Cylindrical 
phantom 
• Depth of Dose. 
• Initial shield 
effectiveness. 
• Simulates Paediatric 
patient. 
 
Stage 2 Cylindrical 
phantom with 
multiple sized 
breast plates. 
• Effectiveness of 
shield for small, 
medium and large 
breasts. 
• Comparison of breast 
shield to Tube 
Current reduction 
techniques.  
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Stage 3 Cylindrical 
phantom with 
medium breast 
plate plus 
additional 
slices to 
increase 
thickness. 
• Effectiveness of 
shield for different 
sized breasts in the 
“Z” direction. 
• Effect of additional 
scatter on dose 
received. 
 
Table 2-2: Phantom summary. 
 
2.3 Thermoluminescent Dosimetry 
 
Thermoluminescent Dosimetry (TLD) is a branch of Medical Physics that utilises crystals with an 
ability to store incident energy, from ionising radiation, and release that energy at a later time in the 
form of visible light. The basic premise behind TLD involves ionising radiation imbuing electrons 
within the crystal to jump to meta-stable states, where they remain trapped within the crystal. 
Annealing the crystal causes the electrons to fall back to their ground state, releasing a photon of 
visible light in the process. The amount of light emitted is proportional to the original absorbed 
dose[110]. An entire TLD system consists of four basic components[111]: 
 
• a passive device that incorporates some means of identification and contains one or more 
radiation detectors 
• a reader which is used for heating the detector after exposure to ionising radiation, and for 
measuring how much light is emitted on heating, in order to determine radiation dose 
• a computer with appropriate software to control the reader, store the data transmitted from 
the reader, calculate, display and store the evaluated dose 
• additional equipment and documented procedures for performing associated processes such 
as deleting dose information, cleaning dosimeters, or those needed to ensure the 
effectiveness of the whole system. 
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As is noted by Kron[110] the complete theory of thermoluminescence is extremely complex and 
beyond the scope of this study. A brief summary of the physics will be given, though emphasis will be 
placed on the procedures and equipment used in this research. 
 
2.3.1 TLD Theory 
TLD uses the principle of phosphorescence to detect and quantify ionising radiation. Some solids 
exist in a state where electrons are only loosely held in molecular bonds, and can exist in a low 
energy state known as the valence band or ground state, and a high energy state known as the 
conduction band[3]. Incoming photons in the form of X-rays or gamma rays can be absorbed by the 
valance band electrons, causing them to shift energy states into the relatively higher conduction 
band. If the electron undergoes a spontaneous and relatively immediate shift back to the stable 
valence band, an electromagnetic emission results. This is known as fluorescence.  
If a material is impregnated with a minute amount of impurities, it is possible to create an electron 
“trap” in the area between the ground state and the conduction band. The area between these 
bands is often referred to as the forbidden band[3]. These traps within the forbidden band create the 
meta-stable state that the electrons can exist in for longer periods of time. The electrons will 
gradually fall back to the ground state with the energy loss differential between the trap and the 
ground state represented by an electromagnetic emission, typically in the visible range of the 
spectrum, a process known as phosphorescence. 
Although the number of trapped electrons will gradually decrease with time, by introducing the 
“charged” crystals to a high ambient temperature we can increase the probability of these 
electromagnetic emissions. This process is known as annealing, and when these crystals are annealed 
within an oven at temperatures of 300-400oc the trapped electrons will fall back in a relatively short 
amount of time. A photomultiplier tube can be used to measure the emitted light, and the amount of 
light emitted is proportional to the original absorbed dose. 
The basic premise detailed above is shown schematically in Figure 2-5 below; 
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Figure 2-5: Process of TLD. 
Although Figure 2-5 shows a simplistic process with a single trap, TLDs often have a multitude of 
different traps, each of which has its own probability of releasing the electrons at various 
temperatures and subsequent time-frame in which this happens. This leads to a variety of light 
intensity functions over the annealing time, and these functions are known as glow curves. 
 
2.3.2 TLD Materials 
The TLD material used in this study is Lithium Fluoride, doped with a minute amount of Magnesium 
and Titanium (LiF: Mg, Ti) commonly referred to as TLD 100. There are a multitude of different TLD 
materials with a variety of different properties and application, a summary of which is provided in 
Table 2-3 below: 
 
Type Materials Applications Density 
(g/cm
3
) 
Effective 
Z 
Fading at 
room temp 
Useful dose 
range 
TLD 100 LiF:Mg,Ti Medical  & 
Health Physics 
2.64 8.2 5%/year 10uGy-10Gy 
TLD 100H LiF:Mg, Cu, P Environmental 
& Personnel 
2.64 8.2 Negligible 1uGy-10Gy 
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TLD 200 CaF2: Dy Low Dose 3.18 16.3 16%/fortnight 0.1uGy-10Gy 
TLD 800 Li2B4O7:Mn High dose 
radiotherapy 
2.3 7.4 5%/3 months 0.5mGy-
105Gy 
TLD 900 CaSO4:Dy Environmental 2.61 15.5 8%/6 months 1uGy-100Gy 
Table 2-3: Properties of commonly available TLD materials, compiled from [110, 112, 113]. 
The benefits of using TLDs for dose assessments have been thoroughly discussed in current 
literature, and are effectively summarised below[114]: 
 
• they are small, easily transported and can be inserted into small holders and containers. 
• they have high radiation sensitivity and large dose ranges. 
• they are dose rate independent. 
• they have long term stability with minimal influence from environmental factors such as heat 
and humidity. 
• they are re-useable. 
• they are suitable for automation, making a high throughput possible. 
• a variety of tissue equivalent materials are available. 
 
Each of these points was considered when deciding to use TLDs as the dose measurement method in 
this study.  
 TLD 100 was the chosen crystal also for several reasons. First, the effective atomic number (8.2) is 
close to that of water (7.5) or tissue (7.64)[115, 116], making them relatively tissue equivalent. The 
relative performance of these TLDs in relation to water in absorbing dose has been tested below in 
Section 2.4 using Monte Carlo Techniques to show that correction factors range from 1.1 to 1.25 as a 
function of incident photon energy, which is consistent with other published data [115, 117-119].  
Second, with the relatively large doses that each crystal is subjected to in this study, the range and 
sensitivity of the TLD 100 was deemed to be more than sufficient. Total doses, and dose increments, 
lower than 1μGy were not considered in this study, nor were doses exceeding 10Gy. The literature 
reports very good linearity between actual dose and apparent dose between the ranges of 3mGy and 
2Gy, outside of these values the sensitivity decreases[110]. 
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The third reason is the presence of an established set of working rules, procedures and equipment 
designed around the TLD 100 crystal rods. As discussed in the IEC 1066 Standard [111] this is an 
integral part of any effective laboratory hoping to return accurate dose results. It is also the main 
reason why TLD 100 rods were used as opposed to TLD 100H. 
 
 The crystals themselves are in the form of a cylindrical rod of diameter 1mm and length 6mm. They 
were housed in purpose built cylindrical containers of diameter 5mm and length 25mm, each 
individually engraved with a unique number. The capsule helped to identify each individual crystal as 
well as protect them from any damage or foreign deposits, both of which can affect light 
emission[113]. 
 
 
 
2.3.3 Checklist for Reporting of TLD Results 
 
Due to the large variety of different equipment and techniques in regards to TLD and analysis, a 
detailed checklist has been developed to include the majority of relevant information that should be 
reported with any study using TLD measurements[120].  This checklist has been completed below: 
 
Figure 2-6: a) TLD crystal rod visible in the capsule. b) A variety of capsules ready for calibration exposures. 
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ITEM Details 
1. DETECTORS  
TLD material LiF:Mg, Ti (TLD 100) 
Manufacturer Thermo Scientific 
Physical form and dimensions Cylindrical rod, diameter 1mm, length 6mm. 
Selection for measurements See Section 3.2.4.3 for details.  
Casing of Detectors Plastic cylindrical containers, 5mm x 25mm 
2. ANNEALING  
Oven type and manufacturer Nucletron PTW-TLDO 
Annealing tray material Copper 
Temperature  400
o
C, 90
o
C 
Heating/cooling rate in 
o
C/min Unknown 
3. READOUT  
Reader type and manufacturer Harshaw TLD 5500 
Spectral sensitivity  
Manual or automated readout Automated readout 
Readout temperature profile Yes 
Use of inert gas Nitrogen 
What additional data was collected Background noise (BN) every 10 rods, fraction of reference 
light (RL) every 10 rods. Individual values are interpolated 
between subsequent readings.  
4. EVALUATION  
Did evaluated data differ from collected, and what 
conversion coefficients were used? 
Raw charge was collected. Individual sensitivity correction 
factors (ISCF), BN and RL correction factors were manually 
applied.  
Mode of calibration 15 rods out of every 50 were used in calibration. Doses 
ranged from about 100mGy to about 1Gy. Linear 
equations were used to convert charge data to dose data. 
See Section 3.2.4. 
Radiation quality used for calibrations Same quality as for CT measurements. No correction factor 
needed. 
Any additional corrections? No 
5. GENERAL  
Typical reproducibility (1 SD) See Section 3.2 
Comments on handling and storage All handling was done with a small vacuum. Any storage 
time between annealing and reading was done within a 
3cm lead container to minimise background dose. 
Table 2-4: TLD reporting information. 
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2.3.4 Procedure details 
All TLD annealing and readings were carried out at the Medical Engineering and Physics Department 
at Royal Perth Hospital. Below is a brief synopsis of the procedures involved in collecting the dose 
data from these TLDs. 
2.3.4.1 Annealing 
During every pre-measurement and post-measurement procedure, care must be taken to minimise 
handling of the crystal rods, and to ensure that rods do not become mixed, as the ISCFs are specific 
to each rod. All handling is done by a small plastic needle tip attached to a vacuum pump to ensure 
that scratching of the rods does not happen, as can be the case with tweezers, and so that the oils 
and dirt from fingers do not adhere to the rods causing errors in the readings[110, 113].  Even so, 
before every use of the TLDs they are soaked in a methanol bath to help remove any excess material 
that may have collected on each individual rod.  
Once cleaned and dried the rods are carefully placed into a numbered copper tray for insertion into 
the annealing oven. The oven is a Nucletron PTW-TLDO that initiates a timed program of annealing, 
with temperatures reaching 400OC. The oven is designed to ensure that even heating is applied to all 
areas of the trays[121]. 
 
Figure 2-7: Nucletron PTW-TLDO annealing oven[121]. 
2.3.4.2 Calibration 
After annealing, the rods are reinserted into their individually numbered Perspex capsules and are 
ready for exposing. An estimate of the minimum and maximum dose that the rods were expected to 
be exposed to were taken using a CT pencil ion-chamber, and it is these values that need to be 
bracketed during the calibration procedure done in conjunction with every experimental phase.  
As per the findings of Section 2.4 the calibration TLDs needed to be exposed to the same beam 
quality as the experimental TLDs would be in the CT. For this purpose a Philips EasyDiagnost ELEVA 
General Radiographic unit was used. The HVL was calculated by inserting increasing thicknesses of 
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99.99% pure aluminium sheeting into the primary beam, until the dose values were halved. This is 
the same method utilised to determine the HVL of the CT, and follows the protocols set out by the 
WA Radiological Council[59]. Factors such as added shielding or kVp could be modified if necessary 
before each calibration to ensure the beam quality corresponded with that of the Philips CT unit. The 
CT HVL was found to be 8.89 mm Al at 120kVp, and a HVL for the ELEVA was found to be 8.86mm Al 
at 120kVp. 
An ion chamber was used to measure the dose of each exposure, and corrections were applied to the 
readings based on the distance from the TLDs that the ion chamber was situated. The heel effect was 
minor over the distances between individual TLD’s however, it was still taken into account, and it was 
found that external TLDs were exposed to doses with a difference of up to about 1%. Solid state 
detectors are often used to measure the output of these general radiographic units, though we 
found differences in dose of over 6% between an ion chamber and solid state detector. This is likely 
due to the inability of the sold state detector to measure back-scattered photons, as they are backed 
with a lead plate. Since the TLDs were placed directly on the table, the ion chamber values are a 
much more accurate assessment of the dose that the TLDs would receive. 
Of each batch of 50 TLDs, 15 were designated for calibration. Repeat exposures were made using the 
ELEVA to give a controlled dose to the TLDs of between 0 and approximately 1Gy. A calibration curve 
could then be generated, such as shown in Figure 2-8 below, which is then used to determine the 
radiation absorbed dose to the TLDs based on the charge released and measured during the readout 
stage. With the large number of exposures required to reach 1Gy, care must be taken to ensure the 
tube does not over-heat! 
 
Figure 2-8: An example of a TLD calibration curve. 
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2.3.4.3 Reading 
Once the experimental and calibration TLDs have been exposed, it is important to wait several days 
before reading them to ensure the short-lived glow curves do not factor significantly into the output, 
particularily if calibration and experimental exposures occur on different days. For example, the TLD 
100’s typically have 8 peaks in the readout glow curve, of which only the first six are used for dose 
determination of low dose readouts (below 2Gy). One of these peaks has a half-life of about 10 
minutes at room temperature and the second peak has a half-life of about 20 hours at room 
temperature. All other peaks have much longer half-lives, as per Figure 2-9 below, adapted from 
[110, 122]. 
 
Peak 
Number 
Read out 
Temp (oC) 
Half Life at 
Room Temp 
I 70 10 min 
II 105 20 hr 
III 130 6 months 
IV 170 10 year 
V 195 80 year 
VI 235 >100 year 
 
Thus, if the calibration TLDs were exposed 1 day after the experimental TLDs and the readings were 
taken the day after that, peak II would be twice as large for the calibration TLDs, and the result would 
be inaccurate. Additionally, it is not possible to read all 300-400 TLDs in one day, so taking readings 
on subsequent days could also cause this to be a factor. There are two methods which can be used to 
alleviate this problem. The first is to perform a pre-read anneal of the crystals, which can be 
performed for about 10 minutes at a temperature of just over 100 degrees[114]. This will release the 
electrons from Peak I and II, and will thus not factor into the readings. The second method is the one 
we chose to utilise, and that was to simply wait a period of time in which the TLDs would fade, and 
the natural half-life of these peaks at room temperature would ensure the level of contribution to 
the final reading would be insignificant. A period of just over a week from the last exposure was 
considered sufficient, as this ensures a complete loss of peak I, and almost 10 half-lives of Peak II, 
which reduces it to a negligible amount of contribution. 
Figure 2-9: a) Schematic representing the TLD100 glow curves. b) The half-life of the glow curves and their typical read 
out temperatures. 
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The actual reading is performed by a Harshaw 5500 TLD reader, which reads batches of 50 per 
analysis. The crystals are carefully placed into circular discs, which are then entered into the reader. 
 
Figure 2-10: a) Harshaw 5500 TLD reader. b) Circular reading disks. 
Each rod is read by the program Thermo-WinRems, and the charge is displayed. Automatic correction 
factors are applied by the program, though only raw data was used for this study, and necessary 
correction factors were manually applied.  
 
Figure 2-11: Readouts of the Thermo-WinRems program. 
Correction factors that are applied include Individual Sensitivity Correction Factors (ISCF) for each 
rod, which are discussed in detail in Section 3.2.4.2, the Reference Light (RL) correction factor and 
Background Noise (BN) value. The reference light is set at an output of 150 nC, and the applied 
correction factor is in reference to the actual measurement taken. The BN amount is obtained purely 
by a measurement with no TLD crystal in the reader. Both of these values are taken at the beginning 
of a batch and at 10 rod intervals, with the value for each individual rod interpolated between each 
reading. So the corrected value is equal to: 
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The final charge value is then converted to an absorbed dose value based on the calibration curve 
calculated for each batch of 50. 
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2.4 Energy Response and water equivalence of the TLDs 
2.4.1 Introduction 
Two factors inherent in the TLDs that could have potential impacts on the accuracy of the readings 
are the ability of the crystal to act as a water (or tissue) equivalent material, and the dose response 
of the crystals as a function of the incident photon energy. Both of these factors will be examined 
below using computer simulations to determine if any additional steps need to be taken in the 
experimental process to account for them.  
LiF is commonly used as the TLD material of choice to determine accurate dose measurements in 
diagnostic imaging, radiation protection and radiotherapy. Its use is based on the effective atomic 
number (8.3) being close to that of water (7.5) or tissue (7.64) [115, 116].  Though since we are 
attempting to simulate the dose received by human tissue, it is important to know how the slight 
difference in atomic number between tissue and the LiF crystal affects the dose scored. Does the 
dose recorded by the TLDs accurately reflect the dose received by tissue? Additionally, does the 
energy of the incident photon beam modify the dose recorded by the crystals? Both of these 
questions have been investigated by the use of Monte Carlo simulations. The EGSnrc code system 
has allowed us to model the response of these detectors to a range of mono-energetic beams and 
compare their dose absorption properties. 
 
2.4.2 Methods 
2.4.2.1 Geometry 
In order to determine the water equivalence of the LiF-TLD, simulation geometry was constructed 
within the EGSnrc Monte Carlo code as shown in Figure 2-12, which allowed the region occupied by 
the LiF cylinder (4mm length, 2mm radius) to be readily removed and replaced with H2O, and the 
dose scored to this particular region was isolated. This allowed a perfectly reproducible and identical 
environment to compare. The region of interest was in the centre of a cylinder of water of radius 
5cm and with 5cm of water above and below this region. The volume of the area of interest was 
confirmed by cross checking the total mass and density outputs, with the desired volume. Both 
methods give a volume of 0.025cm3. 
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Figure 2-12: Geometry of the simulation 
2.4.2.2 Simulation parameters 
A mono-energetic photon beam of diameter 3cm was incident on the central axis. Incident photon 
energies ranged from 0.01MeV up to a maximum of 20MeV within this program, which exceeds the 
requirements for this study. The photon and electron cut-off energies were set at 10keV and the 
energy loss per electron step was 25%. The relatively small area of interest required a large number 
of samples in order to minimise the associated error. Thus 1E6 histories were run for each 
simulation. This kept errors to less than 10% in the dose deposited whilst limiting simulation times 
for each data point to about 1 hour. Similar studies have used a higher number of histories or less 
energy loss per step [119, 123], and although this results in greater statistical certainty, the 
simulation time increases dramatically for each order of magnitude increase. 
The EGSnrc Monte Carlo code requires the simulation material to be defined in a PEGS4 data file. The 
information in these files relates to the interaction probability for multiple radiation types, as well as 
for multiple energies. The “examin” utility function allows us to analyse this data which is 
represented graphically for both H2O and LiF as a function of energy in Figure 2-13 below. 
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Figure 2-13: Relative contribution of interactions to the total cross section of water and LiF. 
The relative contribution of the photoelectric effect, Compton scattering and pair production to the 
total interaction cross section for both water and LiF are shown. As is expected, the photoelectric 
effect significantly drops in relevance as we move above about 30keV, though for our expected 
65keV average photon energy during the study we still see a contribution of about 8%.  The Compton 
Effect dominates until the contribution from pair production begins to exceed that at energies 
greater than 20MeV, all of which is expected from theory[124]. The region of interest for this analysis 
program was 0.01MeV to 20MeV, in which the Compton affect is dominant, and as Figure 2 shows, 
the Compton Effect is more significant for water over these energies, with a maximum percentage 
difference of about 5% at 15MeV and similar differences at 60keV, which means the relative 
difference should be identical for our diagnostic beam when compared to the radiotherapy beam. 
Pair production only comes into play at energies greater than 1.022MeV and contributes about 10% 
of the total interaction cross section for both water and LiF at 6MeV. 
The total photon attenuation figure, measured in cm2/gram, has also been produced using this 
EGSnrc code and the data for both LiF and H2O is displayed in Figure 2-14 and compared to the data 
set provided by the National Institute for Standards & Technology[125]. 
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Figure 2-14: Total Photon Attenuation used for PEGS4 data in this study, as compared to data published by NIST. 
 
Agreement between the data sets generated by the EGSnrc code and that provided by NIST is almost 
absolute, with only minor differences of no greater than 2%. It is quite clear that there is a significant 
difference between the attenuation coefficients for Water and LiF, and from this data we may expect 
a greater dose deposition in water as opposed to the TLD crystals. 
 
2.4.3 Dose Analysis 
The DOSRZnrc user code allowed us to easily alter the energy of the incident beam to determine the 
dose scored as a function of energy. The actual dose deposited in the LiF and the equivalent 
dimensions of H2O, per incident photon fluence, are shown in Figure 2-15. The simulation was 
running an incident photon fluence of 3.537E4/cm2. 
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Figure 2-15: Total Dose deposited in LiF and H2O equivalent geometries. Results are in Gray/Incident Fluence. 
As these results clearly show there is a small difference between the doses scored in the LiF when 
compared to the identical region within a water bath, made up of purely H2O. The extent of this 
relative difference, and thus the water equivalence of the LiF as a function of photon energy is shown 
in Figure 2-16 below. 
 
Figure 2-16: Relative dose scored in H2O compared to the LiF. 
 
The results from this study show a range of relative values. Similar work was performed by Mobit et 
al[119], in which results were similar to this work, though they appear to be of a more consistent 
nature, as shown in Figure 4-16. Mobit used slightly different simulation parameters and only photon 
energies of MeV quality were studied. Even Mobit stated that the correction factor for H2O/LiF 
increased with the quality of the X-ray beam, which is shown by this study. In a subsequent follow-up 
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study, Mobit [126] does conclude that the results of several unpublished energy dependence LiF 
studies varies considerably, and differ from his study by up to 20%. Thus these results are well within 
the expected range. Bistrovic et al.[117] found that the dose response for the LiF compared to H2O 
decreased by 7-10% from the energy levels of a Co-60 beam (1.2MeV) to higher energy photon 
beams between 20 and 42MeV. This study showed an 8.7% decrease in LiF relative response over a 
similar energy range, which is consistent with Bistrovic’s results. 
 
2.4.4 Conclusions 
This study has simulated the water equivalence in terms of absorbed photon dose for a typical LiF 
TLD. The water equivalence has been demonstrated over a range of photon energies, and the results 
obtained show that differences of up to 30% can be expected between the two materials. Water is 
consistently expected to absorb more dose with a clear increase in this relative amount as the 
incident photon energy increases. Although LiF TLDs are relatively a very good tissue or water 
equivalent material, these differences must still be taken into account in dose determination.  
In a practical sense and for the purposes of this study, this exercise has confirmed two main things. 
First, the dose results from the TLD crystals are going to be approximately 10% lower than the actual 
dose that would have been received by water, which is far closer to a tissue equivalent material than 
the LiF. This will only affect the absolute dose values, as the relative values when comparing the 
effectiveness of the bismuth breast shields or dose reduction technologies will still be valid. 
Second, it has confirmed that for a perceived equal dose delivered at varying photon energies, there 
will be a difference between the doses scored of about 20% for CT energies of 120kVp to the LINAC 
energy of 6MeV. As was stated above, TLD analysis is a relative dosimetry technique so all 
experimental results must be determined by the collection of accurate calibration data on a subset of 
the TLDs. The use of the LINAC to perform these calibrations would be preferential as the time taken 
would be reduced by several hours for each set of experimental results. Though with such a large 
dose differential, it was decided to perform the calibrations at the same energy as that which will be 
used in the CT scanning. It was initially proposed that the correction factor obtained above could be 
applied to the calibration data, though the level of consistency of the correction factor at keV 
energies is unfortunately not sufficient to justify this approach. The greater disparity between Lif and 
H20 at diagnostic energies makes it even more important to match the beam quality when 
calibrating. 
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3 RESULTS AND DISCUSION 
 
3.1 Breast shield lead equivalence 
3.1.1 Introduction 
The Attenurad breast shield does not have a manufacturer specifically quoted value for the lead 
equivalence. Vollmar and Kalender[56] have described the shield as providing 0.06mm lead 
equivalence, though the source of this figure is not stated.  F & L Medical Products distributes the 
shields and quotes dose reductions of 57%[75]. Various other studies have shown similar results such 
as Hopper[77] and Vollmar[56] with 57 and 50% respectively. Using these figures we can attempt to 
make an estimate of the lead equivalence, though it was thought that an experimentally determined 
result would be more applicable to the exact shield used within this research. 
 
3.1.2 Equipment 
The generation of the X-rays used in these measurements was performed by the Philips Diagnost 
Eleva general radiographic unit. 
The dose measurements were conducted on an RTI Piranha 657.  
 
3.1.3 Methods 
Initial work was done to determine the Half Value Layer (HVL) of the photon spectrum generated by 
the CT scanner used in this study, at the 120kVp setting. The HVL is defined as the thickness of a 
material required to reduce to initial photon intensity by one half. It was important that the HVL of 
the Philips Diagnost spectrum was as close as possible to that of the CT unit in order to ensure that 
the results would be transferable between experimental phases. An almost identical HVL was found 
by using an 117kVp beam with an additional 0.1mm Cu + 1.0mm Al. See Section 2.3.4.2 for details. 
Repeated measurements of the dose were taken with an increasing number of breast shield layers in 
order to determine the transmission curve, and it is from this data that the lead equivalence of the 
shield can be calculated. 
 
3.1.4 Results and Discussion 
The dose measurements are shown below in Table 3-1. 
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Layers of 
breast shield 
added 
Dose AVG 
0 5.63 5.63 
0 5.63 
0 5.63 
1 2.76 2.76 
1 2.76 
1 2.76 
2 1.65 1.65 
2 1.64 
2 1.65 
3 1.01 1.01 
3 1.01 
3 1.00 
4 0.70 0.70 
4 0.70 
4 0.70 
Table 3-1: Doses measured through various breast shield layers. 
The HVL for the breast shield is found by plotting the relative transmission through the layers of 
shield, as per Figure 3-1 below and drawing down to the shield thickness that corresponds to a 
transmission of 0.5. 
 
Figure 3-1: Relative dose transmitted through multiple breast shield layers. 
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In order to determine the lead equivalence we follow the procedure as defined by Archer[127] which 
is as follows: 
   1 ln
#$ + &
1 + &
 
Where the terms α, β and γ are the fitting parameters defined by Archer and for a 125kVp X-ray 
beam are: 
α = 2.2191 
β = 7.9247 
γ = 0.5387 
The term B is the measured transmission through the shield;   '.)*+.*,  0.49. 
This gives the breast shield a lead equivalence of 0.0753mm, which is slightly higher than the 
0.06mm figure provided by Vollmar and kalendar[56], and is approximately one HVL at a broad beam 
spectrum of 120kVp. 
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3.2 Initial TLD Exposures 
3.2.1 Introduction 
After the purchase and delivery of 300 new TLD crystal rods an initial series of exposures was 
required to determine the consistency and efficacy of each individual rod. This was accomplished 
using a Linear Accelerator and the procedure was designed to provide a consistent and efficient dose 
in the order of magnitude that the experimental work will be carried out. It allowed for the removal 
of any TLD rods that were not performing as designed and also provided Individual Sensitivity 
Correction Factors (ISCFs) for each rod allowing a greater level of accuracy when determining the 
dose each rod will receive during the experimental stage.  
 
3.2.2 Aim 
The main aim of this task was to irradiate 300 new TLDs to a uniform dose of 1Gy on three separate 
occasions to isolate any defective crystal rods and to attribute ISCFs to each of these rods. 
 
3.2.3 Methods & Materials 
300 new TLD-100 rods were supplied by Thermo Fisher Scientific. In order to determine if there were 
any defective rods and to provide us with an idea of how each rod scores dose relative to each other, 
each rod was annealed, exposed to a dose of approximately 1 Gy and read. This procedure was 
repeated three times. This method was similar to that currently recommended by Royal Perth 
Hospital, as outlined in the work by Burrage and Campbell[128]. 
Each crystal rod is contained within a constructed TLD holder as described in Section 2.3. This allows 
for protection of the rod, as well as ensuring rods remain within their individually numbered holder.  
The method of delivery of the Radiation Dose was a Varian Clinac 600C Radiotherapy accelerator, 
operating at 6MV using a field size of 20x20cm. A Linear Accelerator was used for this purpose as it 
would give a uniform and accurate dose in the most time efficient manner possible. The dose 
variation over this area was calculated and modelled as shown in Figure 3-2, below. 
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Figure 3-2: Relative dose scored as a function of area for the LINAC. 
As the image above shows, the dose near the edge of the beam area decreases by a significant 
amount. The profile within the central 10x10cm area is much more consistent and drops by 2.4% at 
the most. 
 
X (cm) Y (cm) Matrix Dose (cGy) Percentage 
(%) 
0 0 83.6 100 
-5 5 81.6 97.6 
-5 -5 82.7 98.9 
5 -5 83.3 99.6 
5 5 82.5 98.7 
Table 3-2: Actual dose recorded for the central 10x10cm area. 
Thus it was decided that by irradiating a 20x20cm area, but only placing the TLDs within the central 
10x10cm area would result in a much more consistent irradiation between each rod.  
Other equipment needed for this procedure included a Farmer cylindrical chamber type 2571 (serial 
number 1227) an NE 2670 electrometer (serial number 160) solid water sheets and a thermometer. 
The chamber was positioned on the central axis with a source to rod distance of 90cm and a uniform 
beam of 6MV photons was delivered to the entire 20x20cm field size. 
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To determine the exact amount of Monitoring Units (MU) to deliver to the rods a number of 
correction factors are applied to ensure maximum accuracy in the final dose. The methodology is 
based on that in IAEA TRS-398[129] and utilises the following correction factors: 
 
kTP;  Factor to correct the response of an ionization chamber for the effect of the 
difference that may exist between the standard reference temperature and pressure 
specified by the standards laboratory and the temperature and pressure of the 
chamber in the user facility under different environmental conditions, 
kelec;  Calibration factor of the electrometer, 
kpol;  Correction factor for the effect of a change in polarity of the polarizing voltage 
applied to the chamber, 
ks; Correction for the lack of complete charge collection due to ion recombination, 
kQ; Correction based on the differences between the quality of the beam used and the 
initial quality of the reference beam, in this case Co-60, 
NDW; Correction factor referring to the initial Co-60 reference beam as compared to the 
beam quality in use. 
 
The absorbed dose to water is calculated using the following protocols: 
 
 
 
 
 
where MQ is the corrected chamber reading under the reference conditions, and thus Dw.Q is the 
absorbed dose to water for the beam quality Q, which in this case is 6MV.  
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Each batch of 300 TLDs was split into batches of 100 to allow them to fit into the 10x10cm irradiation 
area, as per the image below. The TLDs were then enclosed in blocks of solid water to simulate the 
absorbed dose to water parameters. 
 
Figure 3-3: Photograph depicting the TLD irradiation set-up on the LINAC. 
 
The LINAC is first calibrated to ensure a known dose is delivered per MU, and then a defined number 
of MUs are delivered to the TLDs resulting in the doses delivered on the three occasions as per the 
data below. 
Temp oC 21 19.3 23.8 
Press hPa 1009.1 1021.8 1014.4 
*Readings corrected for temp/pressure 
        
  Day 1 Day 2 Day 3 
Readings 
(Gy) 
1.3608 1.3671 1.3789 
1.3605 1.3657 1.378 
1.3607 1.3658 1.3786 
Average 1.3607 1.3662 1.3785 
        
kTP 1 1 1 
kelec 1 1 1 
kpol 0.999 0.999 0.999 
ks 1.0053 1.0053 1.0053 
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kQ 0.9962 0.9962 0.9962 
NDw 1.2074 1.2102 1.2102 
        
Dw (Gy) 1.635 1.645 1.660 
        
No. MUs 200 200 200 
Dose/MU 0.00817 0.00823 0.00830 
        
Absolute dose to TLDs   
        
No MUs 
delivered  
122 122 120 
     
Dose 
(Gy) 
0.997 1.004 0.996 
Table 3-3: Data and calculation information used to determine the actual dose delivered to the TLD's on the three 
separate occasions. 
The dose delivered varied between each day by less than 1% using this method.  
 
3.2.4 Results & Discussion 
Data was collected for each day of exposures, though below is a sample plot for the first day of 
exposures in which the charges (doses) have been converted to a nominal value. 
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Figure 3-4: Nominal charge/dose value for each individual TLD rod for the first initial LINAC exposure. 
 
Initially, the data collected appears to show some fairly significant differences between individual 
TLDs, though a wealth of very helpful information was gleaned from this data including the 
elimination of any batch dependencies, elimination of suspect individual rods and the generation of 
ISCFs. 
 
3.2.4.1 Batch Dependency 
From our very first experimental series, see Appendix B, there was a concern that there were 
dependencies between separate batches of 50 TLDs. Each batch is maintained together and read 
together for the life-time of the TLD. The separate work-load and annealing history of each batch, 
although the same within the batch, is going to be markedly different between batches. This 
dependency appeared to be observed in our initial results, so was of key concern for this test. 
Extracting the mean and standard deviation of the charge stored by each TLD within each batch of 50 
from this data resulted in the following; 
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 Day 1 
Charge 
Day 2 
Charge 
Day 3 
Charge 
Batch Mean St Dev Mean St Dev Mean St Dev 
1-50 3081.8 271.5 2833.2 341.2 3003.5 250.1 
51-100 3074.2 279.9 2924.6 371.8 3012.1 285.4 
101-150 2977.2 274.2 3028.4 279.3 2888.9 271.4 
151-200 3048.5 254.6 3110.0 261.1 2891.7 247.2 
201-250 3085.6 279.4 3102.9 258.3 2817.2 264.3 
251-300 3029.7 284.4 3044.2 288.3 2810.9 266.7 
ALL 3049.5 274.5 3007.2 316.3 2904.1 274.2 
Table 3-4: Comparison of the charge assigned to each TLD batch for each uniform exposure. 
Performing a t-Test on the two batches with the greatest differences in mean, 101-150 and 201-250, 
results in a two-tailed P-value of 0.0531, therefore we cannot say that the means are significantly 
different. This shows that the readings at this stage of the TLD crystals’ lives are not going to be 
affected by any batch dependency. Day 2 exposure began with an error in the exposure to the first 
100 TLDs, and it is this data which has been highlighted in Table 3-4 above. An incorrect field size was 
selected on the LINAC for this exposure, so it is unclear exactly what TLDs received a dose outside of 
the 3% margin of error established for TLDs within the 10x10cm field. This data has been removed 
from all other statistical analysis and the result is a P-Value for Day 2 of 0.137. Though when the 
statistical analysis is done on the Day 3 data a P-value of 0.00108 is obtained, this does show a 
significant difference between the means of batches 51-100 and 251-300. At first, this was quite a 
disappointment, as it implied that batch dependencies develop within several annealing and reading 
processes, which could change the results during the experimental stage. On closer analysis it was 
found that the readings for all of Day 1 and Day 2 were done within a 24 hour period, though the 
readings for Day 3 TLDs 1-100 were taken 2 days before 101-200, which were in turn 2 days before 
201-300. This additional 48 hour period is thought to have been significant enough to bring into 
effect the glow curve Peak number II, which has a half-life of approximately 20 hours[110] as 
discussed in Section 2.3.4.3. This was an invaluable lesson, as it showed the importance of reading 
the TLDs within a relatively small time frame after any experimental work.  
 
3.2.4.2 ISCFs 
As Figure 3-4 above shows, there was a fair amount of individual variation between the TLDs and the 
charge stored on them. The variation from the mean was greater than +/- 20% for many of the rods. 
This in itself is not indicative of the accuracy of the results that we can obtain from the TLDs, as it is 
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the consistency of the readings that is of most importance. Figure 3-5 below shows a representative 
sample of 50 TLDs and the readings that each received during the Day 1, 2 and 3 exposures. 
 
 
Figure 3-5: Nominal charge on individual TLD's for the three separate uniform exposures. 
 
As the plot in Figure 3-5 shows, the consistency between each rod is quite good, with differences not 
exceeding 5%. We were thus able to assign ISCFs to each of the rods to help improve the accuracy of 
the readings during the experimental stages. 
 
3.2.4.3 Elimination of faulty rods 
The third reason for subjecting each rod to three repeated consistent exposures was to ensure that 
any rods that did not maintain a certain level of consistency could be removed. To determine which 
results should be excluded from the analysis a Bland-Altman plot has been created, showing the 
differences between each readings, and comparing it to the average of the two readings. This also 
allows a very simple ‘eye test’ to see if any differences are relative to the magnitude of the readings. 
The plot below compares the readings from Day 2 to Day 3, and similar plots have been crafted 
comparing Days 1 and 2 results, and Days 1 and 3 results.  
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Figure 3-6: Bland-Altman plot used to isolate individual TLD's that do not meet consistency requirements. 
The differences between subsequent readings are not related to the magnitude of the readings as 
Figure 3-6 above shows. The dotted lines represent the mean +/- Least Significant Change between 
the data and are calculated by the following; 
 
  01  √2   
A significance level of 0.05 has been selected for this study, so Z = 1.96 and the LSC can be estimated 
as 2.77   as per the formula above. 
Any rods falling outside of this range have been deemed unsuitable and have been removed from 
any further results. In total, 6 rods of the 300 fell outside this range. 
An additional question that arose from our method of testing the rods as described above is the 
ability to relate doses received by 6MV photons to that received by approximately 140kVp photons 
from the CT used in the experimental stage of this work. Do the rods behave differently when subject 
to higher or lower energy photons, even if the delivered dose should be the same? This problem was 
addressed using Monte-Carlo simulations and has been detailed in Section 2.4, which found that the 
readings are dependent on the incoming photon energy. Thus calibration photon energies and 
experimental photon energies must be the same. 
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3.3 Depth of Dose 
3.3.1 Background 
As discussed in Section 1.3 CT scanners direct X-rays into the patient via a rotating tube that moves in 
a ring around the patient. This is in contrast to typical radiography in which the tube and the patient 
remain stationary, and a simple uni-directional beam of photons is directed at the patient. Thus, 
trying to calculate the radiation dose received by a particular organ or tissue is made more difficult as 
X-rays are entering that particular organ from multiple directions and will have been attenuated or 
hardened to varying degrees.   
As the X-ray beam is attenuated by tissue we can expect several processes to occur at significant 
levels in diagnostic imaging. First, a proportion of the photons will undergo the photoelectric effect, 
which at a basic level involves the photon being totally absorbed by an inner shell electron, which 
uses that energy to overcome the binding energy of the atom. This free electron will be absorbed 
almost immediately, but the gap left by its ejection will be rapidly filled with an outer shell electron, 
which creates an additional characteristic X-ray[130]. 
Second, the photons will undergo multiple scattering processes, though the most significant scatter 
process at diagnostic energies will be Compton Scattering. This involves the absorption of a photon 
by an outer shell electron, and the subsequent creation of another photon with less Kinetic Energy 
than the incident photon, the energy of which is determined by the angle of emission.  Simplistically, 
we can use an analogous situation of 2 billiard balls colliding to describe the interaction process[130]. 
The end result is an extremely complex mix of absorption, creation and scatter, ensuring that 
accurately determining the radiation dose deposited in a tissue will be a difficult process. The 
difficulty is only further enhanced by the multiple directions of incoming photons in a CT scanner!  
One of the initial research aims of this project was to determine how the dose deposition varies as 
we move deeper into tissue. One prominent research team stated: 
The present study also demonstrated, although not unexpectedly, that the absorbed radiation dose 
increases with the depth of penetration into each breast[79]. 
Further details are provided that attempt to explain this increase in dose as we move deeper into the 
tissue, and indicated that it is due to the beam hardening that occurs – the “quality” or average 
energy of the beam increases as the Photoelectric effect is more likely to occur for lower energy 
photons. Thus lower energy photons are preferentially absorbed, leaving a higher average energy 
 
55 
beam as we move deeper into the tissue. An increase in the dose may also be observed as we move 
deeper into the tissue by the presence of secondary charged particles such as free electrons and 
positrons created during this absorption process, which potentially create further ionisation events 
after being ejected. 
This phenomenon is often described in Radiotherapy Physics, where there is a build-up period 
directly after the skin surface in which the dose deposited continues to grow until it reaches a 
maximum, and then falls almost exponentially[131] down after that point, as shown below in Figure 
3-7; 
 
Figure 3-7: Diagram representing the dose build-up seen with Megavoltage photon beams incident on tissue. 
Dmax is observed within Megavoltage ranges for water to vary from approximately 1cm to 5cm depth, 
but is not expected for superficial beams (30-80kVp) or orthovoltage beams (100-300kVp)[131]. 
In contrast to the research by Parker et al.,  Hopper [77] states that: 
Radiation dose is maximum on the surface of the patient, decreasing to about half in the centre of the 
patient. 
This statement also appears consistent with other research[132, 133]. This phenomenon could be 
explained by the fact that low energy photons are preferentially absorbed by the tissue, and it is this 
Photoelectric Effect that results in dose deposition. Thus, as we move deeper into the tissue, the 
beam hardens and makes it much less likely that photons will undergo the Photoelectric effect, 
thereby reducing the dose as we move deeper into the tissue. The total attenuation cross-section 
 
56 
does also include the scattering processes, which will also reduce the intensity of the primary beam 
as the depth of penetration increases. 
3.3.2 Aim 
Accurately determining the dose received by various organs and tissues is a key component of 
Medical Physics. The relationship between depth and dose is of critical importance if accurate 
dosimetry of radiosensitive organs, specifically the glandular tissue within the breast, is to be 
performed. 
The goal of this area of the study is to determine where the maximum dose deposition occurs during 
CT scanning and to determine the relationship between depth of tissue and radiation dose. The 
contradictory findings of several papers discussed above will be compared to the results found in this 
experimental stage. 
3.3.3 Methods & Materials 
To ensure that purely the depth of dose was looked at in this section, without complicating factors 
such as additional scattering materials or shapes, the simple geometrical phantom was used, 
described as the Stage 1 Phantom in Section 2.2.4. TLDs were inserted into the phantom in a 
1cmx1cm grid fashion to a maximum depth at the centre of the phantom of 8cm. This compares with 
Parker et al. [79] who used depths of just below the surface, 1cm and 4cm. The TLDs were centred 
between the two oval halves of the phantom. The experimental area was the upper right quadrant as 
shown in the schematic below. 
 
Figure 3-8: Cross sectional diagram of the location of the TLD's within the phantom. 
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The CT scanner used was a Philips Brilliance 64 operating at 120kV, 400mAs, 1 second rotation time 
and a collimation of 64x0.625. The total length of the phantom exposed was 40mm, with the TLD 
crystals directly in the centre of this 40mm length. This identical scan was repeated multiple times to 
achieve maximum doses within the order of approximately 1Gy.  
To help determine the total number of repeat scans required, a Keithly CT pencil chamber was placed 
on the apex of the phantom to determine the maximum dose likely to be received by an individual 
TLD crystal for a single scan. This value was compared to the dose value maximum of 1Gy, and the 
total number of required scans was calculated. This relatively large dose was used to help minimise 
any errors that may be present if only a single scan was undertaken. Performing multiple scans also 
ensures that any areas of slight overlap or slight break between exposure periods during a single 
tube rotation are rendered irrelevant.  
3.3.4 Results & Discussion 
Figure 3-9 below shows a three dimensional contour plot of the Absorbed Dose (Gy) for the upper 
right quadrant of the Stage 1 Phantom.  
 
Figure 3-9: Three dimensional contour graph showing the dose as a function of area. The graph is representing the upper 
right quadrant of the phantom, with the individual axis marks representing a 1cm distance and the point 0, 0 represents 
the very centre of the phantom. 
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The “sternum” axis is representing the central inner part of the phantom. Extracting a two 
dimensional cross section of this data, we can show how the dose varies in a single plane, from the 
surface of the phantom to the central axis of the phantom, as per Figure 3-10 below. 
 
Figure 3-10: Two dimensional representation of the dose as a function of depth into the upper right quadrant of the 
Stage 1 phantom. 
 
The countour plot above clearly shows the decrease in absorbed dose from the outside surface to 
the centre of the phantom. This is further emphasised by the second 2D plot, which clearly shows the 
reduction, and contains the asymitope of dose as we reach deeper areas, similar to that expected for 
MeV photon beams. 
Other points to note include the relative dose reduction as we move around the surface of the 
phantom following the circumference of the oval. This fits perfectly with our expectations, as in the 
latitudinal direction the X-ray beam needs to travel through a maximum distance of perspex of 32cm, 
during which time significant attenuation will occur. In the longitudinal direction, the maximum 
distance of attenuation is 16cm. There is likely to be a slight off-set in the one direction, as the 
“sides” of the phantom will be closer to the X-ray source for a period of the exposure. Thus a small 
factor will be expected to increase the dose in this area, though the attenuation occuring by the 
opposite beam direction obviously outweighs this minor inverse square law increase. 
These results present here show that the theory that Parker et al.[79] proposed, that the increase in 
absorbed radiation dose as depth increases is related to increasing beam quality, may not be correct. 
Section 3.4 will explore this result in more detail. 
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3.4 Breast Shield Effectiveness – Geometric Phantom 
3.4.1 Background 
In conjunction with the depth of dose experimental phase described in Section 3.3, the basic 
effectiveness of the bismuth breast shield was also tested. Section 1.4.4 discussed the effectiveness 
of the breast shield in a variety of other studies and also introduced the manufacturer’s claim of a 
57% dose reduction when using the shield. It is unclear exactly what this 57% reduction is referring to 
in regards to the testing conditions in which this figure was calculated. It is postulated that irregularly 
shaped objects may influence the radiation dose to a certain degree, so to get an early indication of 
the general effectiveness of the breast shield we decided to use the very simple geometric phantom 
with no additional attachments. This will ensure the experiment is kept as simple as possible to get 
an accurate picture of the breast shield’s effectiveness in as close to a perfect environment as 
possible. 
The second major advantage of performing the test in this manner is the ability to gain an 
understanding of how the radiation dose is likely to be affected by the shield in a paediatric CT scan, 
as the shape is approximately representative of a pre-adolescent child. The perfect oval shape is a far 
closer representation of a paediatric patient than the subsequent breast attachments will shape it 
into. Two other major factors are going to influence the total dose received in a clinical environment. 
The first is the ability of operators to use specific protocols for smaller patients, which generally use 
lower exposure factors than for a typical adult scan. The second is the availability of Attenurad 
bismuth breast shields that are designed for paediatric patients. This includes a smaller overall size as 
well as slightly lower lead equivalence values. Both of these factors are discussed in Section 1.5. 
Although these factors should modify the total dose received, the dose comparison in relative terms 
will still be perfectly relevant.  
3.4.2 Aim 
The aim of this experimental phase was to determine the dose reduction capabilities of the bismuth 
breast shield in a perfect geometric environment, before we begin to introduce additional 
confounding factors. It is believed that the results from this phase will give an accurate 
representation of the relative radiation dose that would be received in a select age bracket of 
paediatric scanning. 
3.4.3 Methods & Materials 
The experimental set-up was identical to that in Section 3.3, the only difference being that results 
were obtained firstly without the bismuth breast shield in place, and then secondly with the breast 
shield protecting the phantom and TLDs.  
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3.4.4 Results & Discussion 
The contour graphs below in Figure 3-11 show the dose to the phantom quadrant representing the 
chest area both with and without the breast shield in place.  
 
 
Figure 3-11: Three dimensional contour plot of the dose received by the upper right quadrant of the Stage 1 phantom 
without the bismuth shield, and with the bismuth shield. Each tick mark represents a 1cm distance and the point 0, 0 
represents the very centre of the phantom. 
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The dose without the breast shield shows the same smooth contours as described in the 
experimental phase looking at the depth of dose. The second diagram shows far less uniformity. This 
could be a result of inaccurate TLDs, or which may be caused by the Bismuth shield creating 
secondary electrons when it is hit by the ionising photons. Regardless, the nominal dose values are 
clearly lower with the shield in place, though as mentioned above, the nominal values may not be 
perfectly representative of a paediatric patient as a lower kVp would likely be used. The next 
diagram, Figure 3-12, shows the percentage of dose reduction as a function of location through the 
phantom quadrant. 
 
Figure 3-12: Three dimensional contour plot showing the percentage of dose reduction afforded by the bismuth breast 
shield for the upper right quadrant of the Stage 1 phantom. 
As this graph clearly shows the largest dose reduction in this case is at the surface of the phantom 
and tapers down to a smaller percentage reduction towards the centre. The implication of this is 
highly positive, as it is at the surface of the chest that the radiosensitive glandular tissue is going to 
be located for a paediatric patient. The lower dose reduction towards the centre allows for a 
relatively higher level of image quality to be maintained. 
In regards to the accuracy of the manufacturers’ claim, the average dose reduction over the entire 
chest quadrant is approximately 37%, with a maximum dose reduction of 56% observed. The claim by 
F&L Medical Products is that a maximum of 57% dose reduction can achieved, so this value is likely to 
have been obtained by similar means to this experiment.  
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3.5 Breast Size Dose Analysis 
3.5.1 Background 
 
As was discussed in section 1.2.6 the human breast varies markedly in the overall size and shape, as 
well as in the amount and location of the radiosensitive glandular tissue. These differences are 
present due to individual factors such as age and genetics. Though as a result of environmental and 
cultural factors, the population average has changed over time, and large differences are also 
observed between countries or locations. 
It is not feasible to conduct a study that looks at the efficacy of every individual scenario, though the 
design of our phantom allows for a rapid and effective modification of the size and shape of the 
breast in order to look generally at how the size and shape can change the dose reduction 
capabilities at the disposal of the user. 
At the time of this writing no study could be found that has looked at the changes of dose reduction 
capabilities of a bismuth breast shield in regards to the size of the breast in a CT environment. This is 
an interesting concept as there is a large body of evidence that shows breast size is a risk factor for 
late adverse effects from a variety of radiotherapy treatments [134-136]. This does not necessarily 
transfer directly to diagnostic doses, but implies that larger breasted women may be at greater risk 
of developing a breast cancer as a result of a diagnostic CT scan. This is also coupled with the fact 
that larger breasts may also require larger exposure factors resulting in a greater dose to begin with.  
Mammography work highlights the differences in dose received as a function of breast size, as well 
as for various distributions of glandular tissue [35, 39, 137, 138]. Although specifics are hard to 
quantify, it is believed that an understanding of the dose reduction properties as they vary with 
breast size will be beneficial in optimising the dose/image quality paradigm present in diagnostic CT 
scanning as well. 
For the purposes of this study the breast size was modified in two ways. The first was in the “X 
Direction” which corresponds to increases and decreases in the anterior/posterior direction. The 
second was in the “Z Direction” which corresponds to an increase and decrease in the 
superior/inferior direction of the patient. Photographs can be found for the Stage 2 and Stage 3 
phantom in Section 2.2.4. 
Indirectly, the modification of the breast size in the Z Direction did allow us to test whether or not 
the size of the phantom in this direction would modify the doses received, as a greater thickness in 
the phantom is likely to create a larger amount of scattered radiation.  
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Noise values have been collected for the purposes of this section in order to determine the increase 
in noise that the bismuth breast shields cause, as well as to determine if the additional thicknesses of 
material create any additional scatter, even without the breast shield in place. Breast tissue is 
inadvertently irradiated when patients are typically referred to chest CT examinations in order to 
analyse the lung or heart. It is not the aim of the breast shields to reduce the dose to these two 
organs, but simply to reduce the dose to the breast tissue whilst still maintaining a suitable image 
quality in the regions of interest. 
 
3.5.2 Aim 
 
The first aim of this section of the research is to determine if the effectiveness of the bismuth breast 
shield is altered when the size of the breast is modified. This theory will be analysed for a 
modification in size in the X and Z directions. 
The second aim is to gain a better understanding of the change in dose that may be seen due to the 
increased scatter generated by increasing the thickness of the breast plate attachments.  
It should be noted that all these results need to also take into account the qualitative and 
quantitative noise created within the image as a result of using the breast shield. 
 
3.5.3 Methods & Materials 
 
The same methodology was applied in this section as for the previous experimental work. A number 
of repeated scans were done to get a maximum dose of approximately 1 Gy for each case. The Philips 
CT scanner was set at 120kV and 400mAs with a 1 second rotation time for a 40mm increment 
situated directly over the TLDs’ positions. The collimator was set at 64x0.625mm with a lung field 
filter at high resolution.  
The first section involved using the small, medium and large breast plate attachments, Phantom 
Stage 2, both with and without the breast shield. The number of TLDs placed into the small plate was 
21, with 2 additional rods inserted back into the ‘chest’. The medium plate contained 36 plus 6 in the 
chest and the large had 49 in the breast plus 6 in the chest. The additional rods for the chest area 
allowed us to also measure the reduction of dose to the chest area under these circumstances by 
comparing the values to those obtained in the Depth of Dose experiment, Section 3.3. 
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The second section used only the medium breast plate, both with and without the breast shield. The 
modifications made included adding 1 additional 7.5mm slice of Perspex to each side of the breast 
plate (15mm total), then 2 additional slices (30mm total) and finally 3 additional slices (45mm total). 
This was described as Phantom Stage 3. Each experimental run had 35 TLD crystals. Photographs and 
diagrams for each stage are outlined in Section 2.2.4. 
In order to effectively measure the noise within the images the standard deviation of the pixel value 
(CT Number) was measured on three images in the exact same areas for each series. The average of 
these values was used. Only one image value would really be necessary, as the standard deviation is 
collected from over 12,000 voxels, though it was decided to use three images to ensure the impact 
from an erroneous pixel value/CT number is minimised. 
Values were collected for two separate areas that were chosen to represent noise values for both the 
heart and the lungs. General anatomy as shown below in Figure 3-13, [139] was used to locate the 
typical area occupied by these two organs, and ROI’s were selected as shown in the diagram, with a 
corresponding cross section of the phantom also displayed. 
 
Figure 3-13: Cross sectional image of a chest showing the heart and lung ROI selected for this study. 
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Figure 3-14: Cross sectional image of the phantom showing the heart and lung ROI selected for this study. 
The red square in the centre represents the noise value for the heart, and the blue rectangle shows 
the lung ROI. In particular reference to the lungs, it is obvious that the ROI only makes up a small 
proportion of the entire lung area. Since we are looking at relative noise values, a representation that 
is consistent between images, and between experimental phases, is more important than getting a 
perfectly accurate nominal value of the entire area in question. 
 
3.5.4 Results & Discussion 
 
3.5.4.1 X-Direction 
The average dose reduction when using the bismuth breast shield is summarised in Table 3-5 below. 
Breast 
Plate 
Number 
of TLDs 
Mean Breast 
Dose Reduction 
(%) 
St Dev 
(%) 
Increase in 
Heart 
Noise 
Value (%) 
Increase 
in Lung 
Noise 
Value (%) 
Mean Chest 
Dose 
Reduction 
(%) 
St Dev 
(%) 
Small 21 21 7.7 31 37 42 4.5 
Medium 36 27 6.0 27 35 41 2.2 
Large 49 44 6.1 23 36 43 5.3 
Table 3-5: The average dose reduction and noise increase when the bismuth breast shield is used for the small, medium 
and large breast plate attachment. Values are referenced to those obtained with no breast shield. 
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It should be noted that the number of samples for the chest dose reduction was minimal, as outlined 
above, and the results are for interest only, as the dose reduction to the breast tissue is of 
importance in this study. 
As the data shows there is still a definite reduction in the radiation dose to the breast tissue when 
using the bismuth breast shield. There is also a significant increase in the noise for the pertinent 
organs. This set of experiments also showed a clear distinction between the dose reduction 
capabilities of the shield for different breast sizes, with large breasts showing a greater dose 
reduction effect.  
One additional interesting point to note is the apparent disparity between the results found in the 
depth of dose, Section 3.3, which found the greatest dose reduction percentage near the surface of 
the phantom. The anomaly is the fact that the smaller breast plate showed the lowest dose reduction 
percentage. It was shown in Section 3.4 that the breast shield appears to create a lot of localised 
dose variations closer to the surface, with large peaks and troughs in the amount shielded, which 
would adversely affect the smaller breast plate to a greater degree. The creation of secondary 
electrons by the bismuth shield may also help to explain this and is discussed in further detail below.  
The increase in noise is fairly consistent between each different size for the lung field, which is 
situated much closer to the breast and shield. The increase in noise for the heart field, which is much 
more central to the entire phantom, is far more pronounced for the smaller breast. Looking at these 
sample images below, we can visibly see some streaking artefact caused by the shield. These 
artefacts are present in the areas closer to the shield and tend to disappear as we move deeper into 
the phantom.  
 
a) b) 
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Figure 3-15: Sample images of the small, medium and large breast plate attachments, both with and without the breast 
shield. Streaking artefacts, qualitative noise, are clearly visible in images with the breast shield. 
The streaking is clearly visible, though the amount that is visible to the naked eye is fairly minor 
within the actual chest region, as most of it is contained within the actual breast. Interestingly, the 
larger breast appears to create a greater amount of streaking into the chest area, though the 
increase in noise value from the application of the shield is in fact less than that of the smaller breast 
plate. These diagrams also show the location of the TLDs, and small white dots can be seen in all the 
holes that contained rods during that experimental phase. 
There is no nominal value of noise that we can use as a threshold for acceptable or unacceptable in 
these images. We can say that the qualitative noise created in these situations is very minor for the 
diagnostic region of interest, and the increase in quantitative noise is acceptable when the dose 
reduction of the breast tissue is so pronounced. 
e) 
d) 
f) 
c) 
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Several other interesting concepts were found in the analysis of these results. The contour graph 
below shows the level of dose reduction throughout the entire area of the breast. 
 
Figure 3-16: Three dimensional contour plot of the large breast plate, not including the chest area, showing the dose 
reduction percentage when using the bismuth breast shield, as a function of area. Individual tick marks represent a 1cm 
distance. 
If we extract the average dose as a function of depth in both the X and Y directions, as pictured on 
the adjoining example, we see some clear trends that are present for each of the different breast 
plate sizes. The average dose reduction when using the bismuth shield actually increases as we move 
deeper, or posterior, into the breast (following the Y Axis). After about 2cm the average dose 
reduction does appear to level out. This initial drop in shield effectiveness is likely due to secondary 
electrons created by the absorption of incident photons adding slightly to the dose received when 
the shield is in place. These electrons are unlikely to penetrate any more than 2cm into the phantom, 
which is as expected for beta particles. There must also be contribution due the shape of the breast 
plates, as this trend does appear to be at odds with the case shown previously in which the dose 
reduction for the simple geometric ‘chest’ phantom was greatest at the surface. 
 
Figure 3-17: Explanation of the X and Y direction terminology used in these figures. 
0
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Figure 3-18: Average dose reduction as a function of depth in the Y direction. 
 
In contrast to this trend, when we follow the average dose reduction as a function of depth along the 
X axis, or laterally to the phantom, we see an increase in the effective dose reduction at either end, 
with a dip in the middle. Referring back to the original contour graph above these trends can actually 
be observed.  
 
 
Figure 3-19: Average dose reduction as a function of depth in the X direction. 
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3.5.4.2 Z-Direction 
 
When the medium sized breast plate is used, and the thickness in the Z Direction or superior/inferior 
is increased, the corresponding dose reduction and noise value increases observed are detailed in 
Table 3-6 below. The additional thickness of 15mm corresponds to the addition of a 7.5mm sheet to 
each side. 
 
Additional 
Thickness 
(mm) 
Number 
of TLDs 
Mean Breast 
Dose Reduction 
(%) 
St Dev 
(%) 
Increase in 
Heart 
Noise 
Value (%) 
Increase 
in Lung 
Noise 
Value (%) 
15 35 46 3 25 37 
30 35 44 3 26 38 
45 35 45 3 26 35 
Table 3-6: Dose reduction and nose increase with the use of the bismuth breast shield when the thickness of the breast 
plate in the Z direction is modified. 
 
As these results indicate the additional breast plate thickness had no measureable effect on the dose 
reduction capabilities of the breast shield, nor did it modify the noise value from the initial values. 
Looking purely at the doses received before the application of the shield and after the application of 
the shield we can also see that there has no statistical change in these factors, as shown in Table 3-7 
below. 
 
Additional 
Thickness 
(mm) 
Number 
of TLDs 
Average 
Unshielded 
Dose (mGy) 
St Dev Average Shielded 
Dose (mGy) 
St Dev Mean Breast 
Dose 
Reduction (%) 
15 35 687.5 40.5 373.4 16.7 46 
30 35 700.8 40.5 391.4 17.2 44 
45 35 696.4 46.1 385.1 19.5 45 
Table 3-7: Actual dose data before and after the application of the bismuth breast shield when the thickness of the 
breast plate in the Z direction is modified. 
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These results are not entirely unexpected. The X-ray tube is going to continue to rotate and exposure 
the breast plates with given exposure factors, and the distance it travels has no effect on this. The 
only increase in dose we may see would not be due to additional primary photons or scattered 
photons, as these would exit the patient, but from secondary scattered photons. This means photons 
that would have been scattered out of the patient, but are instead re-scattered by the additional 
thickness of Perspex back into the central area where the TLDs are situated. It is likely that this is 
occurring, though the increase in dose and noise is insignificant compared to the resolution available 
in our testing methodology. 
 
The increase in breast plate thickness, corresponding to an increase in the breast size in the 
superior/inferior direction of a patient, is likely to lead to an increase in the total radiation dose 
received by the breast. Though as these results have clearly demonstrated the absorbed dose, or 
dose per unit mass, is not likely to change to any significant degree. 
 
This experimental phase has shown several important concepts. Firstly, the bismuth breast shield 
effectively reduces the absorbed dose to the breast; with larger breasts appear to have a greater 
average dose reduction than smaller breasts. Secondly, there is a significant increase in the 
quantitative noise values for each different plate size. The noise increase is fairly consistent in the 
lung field region, though the smaller breast plates showed a much greater increase in heart noise 
with the addition of the breast shield. The qualitative noise is present in the form of streaking, 
though it is predominately situated in the breast area, which is of no great significance in terms of 
maintaining a diagnostically useable image. 
 
And finally, increasing the thicknesses into the Z direction of the breast plate did not change the 
dose, the dose reduction capabilities of the bismuth shield or modify the noise value in any 
noticeably significant way, given the errors present in this form of detection and analysis. 
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3.6 Manually reducing mA 
 
3.6.1 Background 
One of the key basic tenets of medical radiation physics is that radiation dose is directly proportional 
to the tube current, mA[3, 140]. This means that if we double the mA, we double the dose. Based on 
this logic, if we are using a CT protocol that uses a fixed mA, then we can expect to see an equivalent 
decrease in radiation dose if that tube current is decrease. The trade-off of course, as discussed in 
Section 1.3.2 above, is that by increasing the radiation dose we get a decrease in the noise within the 
image. This is the basis for the balancing act between radiation dose and image quality in medical 
imaging diagnostics.  
We have seen in subsequent experimental phases of this research that using the bismuth breast 
shield does effectively reduce the radiation dose to the breast tissue. We have also seen that this 
dose reduction comes at a cost. This cost is the increase in quantitative noise within the image, and 
also some slight qualitative noise increases in the form of streaking. The question thus arises, is it 
possible to simply use a lower fixed mA to reduce to radiation dose to a level that is equivalent to the 
dose reduction seen by the bismuth breast shield? The answer to this is unequivocally yes, but this 
leads to the next question; how do the lung and heart noise values compare with an equivalent dose 
reduction to the breast tissue from these two methodologies? We would not expect to see any 
increase in the streaking as a result of manually lowering the mA, but both methods will see an 
increase in quantitative noise. 
It may seem initially that since the noise is related to the mA or radiation dose that there would be 
no difference to the noise value for an equivalent dose value. But we need to remember that we are 
looking at reducing the radiation dose to the breast tissue, whilst minimising the noise value in the 
organs of interest, which are likely to be the lungs and heart, not the breast. As we found in Section 
1.4.4 several studies that looked at the effectiveness of these breast shields stated in their final 
conclusions that a greater dose reduction to the breast tissue could be achieved by simply reducing 
the current on a fixed mA protocol and maintaining a fixed noise value[56, 61]. Neither paper 
explains how this conclusion was reached. 
Multiple events will be occurring which will alter the breast dose/chest noise relationship. The 
bismuth breast shield will remove the lower energy photons preferentially which would ordinarily 
only penetrate a small distance before being absorbed by the breast tissue, whereas lowering the mA 
will reduce the entire spectrum of photon energies the same relative amount. This would imply that 
the bismuth breast shield will lower the dose to the breast, but still allow a relatively higher number 
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of harder photons to penetrate to the torso area. Thus we would see a greater dose reduction in the 
breast tissue than by simply lowering the mA to a level that would maintain an identical noise value. 
On the other hand, the bismuth breast shield is also likely to cause additional beta particles with the 
ionisation processes occurring in the shield, and even a significant number of additional photons via 
Bremsstrahlung X-rays from the high density bismuth. We may also expect the shield to create 
additional Compton scattering events. These factors are likely to result in the bismuth shield creating 
additional noise that we would not see if we simply lowered to tube current. 
 
3.6.2 Aim 
Due to these conflicting factors only an experimental phase will be adequately able to answer 
whether or not a bismuth breast shield can provide a greater breast dose reduction, whilst 
maintaining an equivalent noise value that we would see by simply lowering the tube current in a 
fixed mA protocol.  
 
3.6.3 Methods & Materials 
The radiation dose will rise in direct proportion to the tube current when no shield is in place. 
Therefore it is only necessary to measure the average breast dose in the unshielded breast for a 
single tube current, and the radiation dose can be calculated mathematically for all other tube 
currents required. The noise values will not rise in direct proportion to the tube current, so these 
were calculated by measuring the noise within the heart and lung ROI for the geometric phantom 
with only the medium breast plate attachment in place. 
Apart from the modification of the tube current, the CT scanner protocols remained constant 
between this phase and the previous experimental phase of the study – see section 3.3. 
 
3.6.4 Results & Discussion 
Table 3-8 shows the noise values extracted for the lung and heart ROI’s based on the tube currents 
selected. It also shows the mean breast dose for that tube current. Breast dose values have been 
mathematically calculated based on the dose received during the previous experimental phase for 
400mA. The mean dose for the shielded value was also determined experimentally as per section 3.5. 
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Tube Current (mA) Heart Noise Lung Noise Mean Breast Dose 
(mGy) 
30 519 415 52 
50 386 303 86 
100 234 214 173 
150 213 170 260 
200 185 150 347 
250 166 131 434 
300 150 120 521 
400 129 104 694 
500 116 93 868 
400 (WITH SHIELD) 180 161 383 
Table 3-8: Breast dose and noise as a function of tube current. 
 
 
Once this noise data is plotted in Figure 3-20 we can see the relationship between the noise and the 
current for the Philips CT scanner used in this study.  
The following graph has plotted the relationship between tube current and breast dose, and the 
correlation co-efficient of 1 is expected because we used a perfectly proportional relationship to 
calculate these values. 
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Figure 3-20: Relationship between noise, both heart and lung, and tube current. 
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Figure 3-21: Mean dose as a function of the tube current. 
The next stage is to calculate the tube current that gives us a noise value that is the equivalent to 
using the bismuth breast shield for each ROI.  
We then need to work out what the dose is in an unshielded situation and can compare this value to
that experimentally determined for the shielded value. 
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deviation of the noise readings and the standard deviation of the original breast dose. The average 
dose experimentally determined for the fixed mA protocol when using the breast shield was 
calculated to be 383mGy. Thus, for the medium breast plate in this experimental set-up, a 
statistically lower radiation dose can be received by the breast tissue by simply manually lowering 
the mA in a fixed mA protocol, than by using the bismuth breast shield, at a constant noise value. To 
phrase it in the alternative, an identical breast dose will come with a greater quality of lung and heart 
image if the tube current is manually lowered than by using a bismuth breast shield in a fixed mA 
protocol.  
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3.7 Dose Modulation 
 
3.7.1 Background 
The previous experimental phases have looked at ways to reduce the breast dose under a variety of 
different circumstances, though in each phase the tube current has remained constant during each 
individual scan. Section 1.4.2 introduced a variety of dose saving options available for CT scans, one 
of which was the ability of the scanner to automatically adjust the tube current during the scan. This 
is known as Dose Modulation or Tube Current Modulation. Dose Modulation has the ability to reduce 
the radiation dose significantly, though as always, the image quality is of critical importance. 
It was stated in Section 2.1 that the Philips CT scanner used in this study has two different types of 
dose modulation. Z-DOM adjusts the tube current based on the scout scan taken before the image 
proper. D-DOM adjusts the current each rotation during the scan proper, and is based on the 
symmetry of the patient. This presents multiple options for the potential integration of the bismuth 
breast shield into routine CT scanning, outside of simple fixed mA protocols. 
Simply comparing the breast doses received by the dose modulation techniques directly to a fixed 
mA protocol may not have universal applications, as protocols vary markedly between practices. 
Thus to say that a fixed mA protocol gives a greater radiation dose than a dose modulated technique 
may be correct for one protocol but not another. This first phase will simply compare the two dose 
modulation techniques to each other. We do still have other options available to us though which 
will be expanded on below. The next and final phase of the experimental work will attempt to 
compare each of the options available to the fixed mA protocol used for the majority of this study to 
determine if one single option results in the lowest breast dose and highest image quality. 
 
3.7.2 Aim 
The aim of this experimental phase is to compare the Philips Dose Modulation options in terms of 
their ability to reduce dose and maintain a suitable noise level, as well as determine the effectiveness 
of using the breast shield in a Dose Modulated scan. 
 
3.7.3 Methods & Materials 
Because the Z-DOM protocol uses the scout scan in its determination of the dose for each rotation, 
we have the ability to manipulate the dose received by either not using the breast shield at all, by 
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applying the shield before the scout scan, or by applying the shield after the scout scan. The D-DOM 
protocol changes the current each rotation during the scan proper, so the scout scan will not 
influence the mA selection. Thus two options present itself for this mode of testing – D-DOM without 
the bismuth breast shield and D-DOM with the breast shield. In this case we applied the breast shield 
after the scout. 
The geometric phantom was used in all cases with the medium breast plate attachment and no 
additional thickness. An attempt was made to keep as many factors in the CT protocol consistent 
between these dose modulation scans and the fixed mA scan, though several differences were 
unavoidable. The first difference was a Pitch of 0.891 was required in both cases, compared to a 
pitch of 1 in the previous sections. Secondly, a field of 80.6mm was the minimum field size available, 
which was over double that of the 40mm used previously. Although these differences were 
consistent for all testing done in this phase, correction factors were used in our attempts to compare 
doses between phases. 
 
3.7.4 Results & Discussion 
Table 3-9 below shows the average dose for each of the described techniques, as well as the noise 
value for both the heart and lung ROI. 
Technique Mean Dose 
(mGy) 
St Dev Heart 
Noise 
Lung Noise 
Z-DOM NO SHIELD 349 18 174 168 
Z-DOM SHIELD 
AFTER SCOUT 
204 10 216 205 
Z-DOM SHIELD 
BEFORE SCOUT 
293 13 190 193 
D-DOM NO SHIELD 267 11 194 192 
D-DOM SHIELD 
AFTER SCOUT 
152 7 264 260 
Table 3-9: Mean breast dose and noise values for a variety of dose modulation techniques available on the Philips CT 
scanner. 
 
Plotting this data shows that there is a clear trade-off in these cases with noise value and radiation 
dose. 
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Figure 3-22: Comparison of the lung noise/dose relationship for a variety of dose modulation protocols. 
 
 
Figure 3-23: Comparison of the heart noise/dose relationship for a variety of dose modulation protocols. 
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Without established thresholds for what noise values are acceptable for various diagnostic scans, it 
can be difficult to automatically rule out any particular method, or state that one is better than 
another. Some very useful information can be noted though. Comparing the difference, especially 
noticeable in the lung region, between D-DOM with no shield and Z-DOM with the shield applied 
before the scout, it is clear that for our phantom that the method of applying the shield before the 
scout is never preferable to simply using D-DOM modulation with no shield. Since the over-arching 
aim is to have minimal noise values and minimal dose values, it appears that the best combination 
for the Philips CT scanner is to apply the bismuth breast shield after the scout has been performed 
and use Z-DOM modulation. This of course does not take into account the potential for any 
additional streaking or other qualitative artefacts to be generated by the presence of the breast 
shield.
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4 FINAL CONLCUSIONS 
4.1 Summary Comparison Tables 
Every attempt was made to create a series of experimental phases that could be compared to one 
another to determine if there was a single solution that would provide the lowest breast dose with 
the least noise creation. The following table describes the doses calculated for the medium breast 
plate under a variety of different scanning techniques and protocols and compares them to the noise 
values extracted for the heart and lung regions. 
Technique Mean Dose Heart Noise Lung Noise 
400mA fixed (Standard 
Protocol), No Shield 
696.3 128.9 102.4 
400mA fixed (Standard 
Protocol), With Shield 
383.3 180.8 174.7 
500mA, No Shield 868.6 116.9 93.6 
400mA, No Shield* 694.8 129.0 104.4 
300mA, No Shield 521.1 150.4 120.2 
200mA, No Shield 347.4 185.0 150.1 
100mA, No Shield 173.7 234.3 214.0 
Z-DOM NO SHIELD 348.9 173.7 167.6 
Z-DOM SHIELD AFTER SCOUT 204.4 215.5 205.3 
Z-DOM SHIELD BEFORE SCOUT 293.0 190.3 192.5 
D-DOM NO SHIELD 267.0 193.7 191.9 
D-DOM SHIELD AFTER SCOUT 152.0 263.7 260.8 
Table 4-1: Comparison of breast dose and noise for all the protocols employed in this study. * Values in this row differ to 
that from the alternate 400mA protocol as results were from an alternative experimental phase. 
Table 4-1 contains information for the standard protocol used throughout most the experimental 
work, with and without the bismuth breast shield. It also shows the data collected for fixed mA 
protocols using tube currents ranging from 100 to 500mA. The final half of the table describes the 
multiple Tube Current Modulation options that were investigated.  
Once again, this data has been plotted to try to give a visual guide to the cost/benefit of each 
technique in terms of breast dose and heart or lung noise.  
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Figure 4-1: Summary graph displaying the heart noise/ breast dose relationship for the protocols examined in this study. 
 
Figure 4-2: Summary graph displaying the heart noise/ breast dose relationship for the protocols examined in this study. 
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Without a specifically defined cut-off for an acceptable noise value it is difficult to ascertain the best 
technique. As stated previously the aim of this study is to investigate the various dose reduction 
techniques involving a bismuth breast shield to find the lowest noise and lowest radiation dose. 
Based on the data above we can explicitly say that there are alternatives that provide lower radiation 
dose to the breast tissue, whilst also creating less quantitative noise, than using a bismuth breast 
shield. These other techniques also do not appear to create any additional qualitative artefacts such 
as streaking. 
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4.2 Future Work 
Limitations in time have prevented several logical progressions of this work from occurring. Two such 
experimental ideas are briefly discussed below.  
4.2.1 Maximum Noise Values 
Quantitative noise values have been collected for all the experimental phases and comparisons 
between them have been made. This has allowed us to determine how techniques compare in terms 
of the radiation dose they give to the breast tissue and the noise they create in the image. Without a 
definitive threshold for noise values that make an image diagnostically use-able we are unable to 
explicitly say that one technique should be used in place of another. 
An additional step that could be taken to further advance this work would be to ascertain the 
maximum noise value for individual diagnostic procedures that still allows the Radiologist to 
accurately diagnose the particular issue. This could be achieved by impregnating the phantom with a 
variety of tumour replicating substances, and adjusting the mA of the scans to determine the lowest 
tube current, and associated noise value, that allows these imperfections to be visible. Once these 
values have been established it would be simple to rule out the protocols that exceed these noise 
values and provide an accurate determination of what type of scan technique would provide the 
lowest dose for each procedure. 
4.2.2 Paediatric Comparison 
Very little published work has looked directly at the efficiency of the bismuth breast shields in 
paediatric CT scanning. As discussed in Section 1.5 much of the paediatric work was either performed 
on adult phantoms, with adult breast shield or using typical adult exposure factors. It would be 
advantageous to accurately determine how each of these factors modifies the absorbed radiation 
dose to the breast tissue in paediatric patients. The geometric phantom is already a relatively good 
representation of the torso of a paediatric patient, so paediatric protocols that included lower kVp 
selections, would need to be researched and a paediatric bismuth breast shield could then be tested 
in an identical fashion as to that done for the entirety of this project.  
It is likely that the general trends found in this work when not using any additional breast plates 
would be a very accurate representation of their paediatric efficacy, though with sufficient testing 
this hypothesis could be easily tested. 
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4.3 Limitations of this work 
 
There is one particular area of this study that would justify further analysis, presuming that time and 
other resources were available. The relationship between dose and depth into the phantom was 
clearly displayed in Section 3.3. Though when the breast shield was introduced it became harder to 
directly identify how the dose reduction percentage varies with depth. The breast plate attachments 
themselves also appear to alter the dose distribution within that particular area. So the breast plates 
coupled with the breast shield result in a fairly non-uniform dose distribution to the breast. I believe 
that this area is a limitation of this work, though it could potentially be included in Section 4.2 as an 
area for future work. 
A second major limitation of this work is the confinement of the analysis to a single CT scanner. The 
various manufacturers each have unique ways of dealing with dose reduction and a variety of new 
technologies are always in development – Section 1.4.2. This is again another issue that limited the 
knowledge we could gain in this study, but does always have the potential to be incorporated into 
future work. 
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Appendices 
A: Comparison of breast shield studies 
 
Author Percentage 
Dose 
Reduction 
Noise Shields 
recommended 
for use? 
Notes 
Cordova, 2006[57] 50 Significant increase in 
Qualitative noise 
No Tested Pb Sheets and found similar 
dose reduction, with fewer 
artefacts. 
Fricke, 2003[15] 29 No Increase in Qualitative or 
Quantitative noise 
Yes Used a self-made Bismuth Shield. 
Geleijns, 2006[61] 30 Significant increase in 
Qualitative and Quantitative 
noise 
No  
Hohl, 2006[76] 32 No Increase in Qualitative or 
Quantitative noise 
Yes  
Hopper 1997[78] 57 Not studied Yes  
Hopper 2002[77] 52 Not studied Yes Acknowledged that care in 
placement of the shield is needed 
to ensure artefacts not unduly 
created. 
Hurwitz, 2008[62] 47, 67* No Increase in Qualitative or 
Quantitative noise 
Yes An even greater percentage 
increase was found if used in 
conjunction with lower kVp. 
Parker, 2007[79] 61 Not studied Yes  
Vollmar, 2008[56] 50 Significant increase in 
Qualitative and Quantitative 
noise 
No  
Yilmaz, 2006[80] 37 Not studied Yes  
Table A-0-1: Brief summary of breast shield studies. 
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B: Problems/Issues 
During the course of this experimental investigation several problems arose that created additional 
work and issues that required solving. These issues included, but were not limited to, what we 
perceived as a strong batch dependency between TLDs, requiring repeat experimental phases due to 
dose estimates and Dose Modulation protocols that required different field sizes than what we 
needed. These issues will be briefly discussed below. 
TLD batch dependencies 
The initial depth of dose and shield effectiveness tests, Section 3.3 and 3.4, were performed with 
TLDs borrowed from another facility. The graph below shows the dose reduction percentage found 
throughout the chest quadrant we analysed. 
 
Figure B-1: Initial dose reduction observed in the geometric phantom when the bismuth breast shield was employed. 
Batch dependencies were believed to have caused the distinct tiers. 
What are immediately noticeable are the very distinct “tiers” in this contour graph. We expected a 
measure of difference between the depth of the TLDs and the dose reduction percentage that the 
bismuth shield provided, though this clear definition was obviously an error. Each “tier” in this 
diagram corresponds to a separate batch of TLDs, which are kept together in batches of 50. 
We concluded that this was caused by dependencies between the batches. Each rod within a batch 
has had an almost identical history in terms of life and exposures, though each batch has a 
completely separate history, and this has shown that the history of a TLD can have an effect on its 
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current reading. It would be possible to confirm this by uniform exposures to all TLDs within and 
between batches, and correction factors could be assigned to each rod which would erase this 
systematic error, such as that performed in Section 3.2. It was decided though that we would instead 
purchase our own TLDs and begin the entire process from the beginning. By using TLDs with no prior 
exposure and annealing history we could be as confident as possible that the readings over the life-
time of the project were not going to drift due to differences in work-load between batches. 
Taking this idea one step further we were able to replicate the uniform exposures conducted at the 
very beginning of the experimental work after all the experimental phases had been conducted to 
see if this time period resulted in any major changes to the readings of each individual TLD. 
 
Figure B-2: An example of a batch of 50 TLD's exposed to 3 uniform exposures before the experimental work began, and 
1 equal and uniform exposure after the experimental work had been completed. 
 
The above plot is an example of the data collected, and as can be seen there was a high degree of 
consistency between the pre and post experiment exposures. The total mean of each batch was also 
not statistically significant between these two time frames.  
This final stage was also fairly critical as during the course of the experimental work that used these 
purchased TLDs, a period that extended for approximately 30 months, several TLD rods were either 
lost, destroyed or otherwise rendered unusable and had to be replaced with new rods. These 
replacement rods needed correction factors to be extracted from the above data in order to provide 
accurate results. Due to the high degree of consistency for each individual rod’s readings during the 
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pre-experimental exposures, we were able to use a single exposure for these post- experimental 
results to find correction factors for the replaced rods. During the course of this work a total of 9 
rods of the 300 required replacement. 
This issue resulted in a major set-back near the beginning of the research that resulted in almost 12 
months of wait time to get back to the experimental phase in which we were, though it did teach us 
that it is possible for batch dependencies to form in these TLDs. The end result was a much more 
thorough experimental undertaking that looked very closely at the performance of the TLD100 rods. 
Our results also showed that the time and workload we operated under did not create the batch 
dependencies observed by the borrowed TLDs. 
Repeating experiments  
After sourcing new TLDs in response to the batch dependencies observed as per Section 0, the 
second attempt at determining the depth of dose was attempted. Once the results were analysed it 
was clear that an error had been made in the dose estimates for the TLDs within the phantom.  
The following steps were necessary to perform each single experimental run; 
• Arrange suitable times that Janette and I are available, 
• Ensure the CT equipment is available, 
• Ensure the TLD lab is available for both annealing and reading, 
• Anneal the TLDs, 
• Draft an experimental protocol to follow, 
• Perform the experimental work, 
• Expose the calibration TLDs to known doses with a beam of the same quality factor as the 
CT, 
• Read the TLDs, 
• Create calibration curves and determine the individual doses to each rod, 
• Analyse the results to look for errors etc. 
This is a very time consuming process, so when an experiment required repeating it was a very large 
undertaking in time and resources. Hence why “silly errors” like that described below were very 
frustrating. 
The Keithley Pencil Ion-Chamber was used to provide an estimate of the maximum dose that each 
TLD would be exposed to during each individual scan in order to determine how many scans would 
be required to reach a maximum of 1Gy. The TLD calibrations can then be subsequently performed 
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to ensure that a calibration curve will encompass the entire dose range of the experimental TLDs, 
see Section 2.3.4 for more information. 
When the results were analysed it was found that they were far in excess of the estimated doses, 
thus rendering the calibration curves informational at best, as we would always want to interpolate 
our results, not extrapolate. We realised after significant deliberation that we had failed to 
compensate our readings for the length of the ion chamber exposed. The total length was 10cm, 
though we were only exposing 4cm of that length, thus all readings were corrected for a full 
exposure and the number of repeats we initiated gave doses 2.5 times that required. Unable to trust 
the calibration curves were correct at those doses, the entire phase needed repeating again. 
Collimator Size Effects 
The vast majority of the experimental work with the CT scanner was completed using a collimated 
field length of 40mm, unfortunately the dose modulation procedures required twice that distance 
(80.3mm) to operate correctly. It was thought that this increase in field size would increase the 
amount of scattered radiation and thus increase the doses received by the TLD crystals[140, 141]. In 
itself this was not a major issue, as each Dose Modulation technique, including those with the 
bismuth shield in place, would be exposed to an identical increase in dose as a result, and direct 
comparisons could still be made.  
In the final conclusion in which an attempt was made to compare all techniques used in this study, 
compensation needed to be made between the normal exposures of 40mm and those of 80.3mm. A 
direct comparison was made using identical fixed mA protocols with only the length of the exposed 
area modified. 
The results showed a 2.1% increase in the noise values observed and approximately a 10.1% increase 
in the radiation dose absorbed by the TLDs with the increase in exposed length. These factors were 
then applied to the dose modulated figures to ensure a direct comparison was as accurate as 
possible. 
 
